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ABSTRACT 
 
Central driving forces in the pathogenesis of liver disease are hepatocyte 
death and immune cell-driven inflammation. The interplay between outcomes, 
stemming from these two major cell types, is present from the earliest ethanol 
exposure, and are both determinants in advanced stages of liver disease 
particularly in alcoholic liver disease (ALD). The complexities associated with 
advanced ALD are many and therapies are limited. Due to the liver’s role in 
ethanol metabolism and filtering gut-derived products, it is becoming increasingly 
clear that innate immunity plays a central role in triggering activation of cell death 
and inflammatory pathways in ALD. We identified interferon regulatory factor 3 
(IRF3) activation as a mediator of hepatocyte death as the first event after 
ethanol exposure, and the inflammasome as a protein complex responsible for 
the subsequent inflammatory cascade, driven by the NLRP3 inflammasome.  
Our novel findings in murine samples and human patients with alcoholic 
hepatitis demonstrate that ethanol-induced inflammasome activity results in 
Caspase-1-mediated pyroptosis and extracellular ASC aggregates in the liver 
and circulation. Pyroptosis can be abrogated by therapeutic inhibition of 
inflammasome components, NLRP3 or Caspase-1. Taken together, the event 
leading to mtDNA release into the cytoplasm is the inception of the pathogenesis 
of ALD, triggering hepatocyte death, culminating in a pro-inflammatory cascade 
driven by the NLRP3 inflammasome and pyroptotic release of ASC.   
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PREFACE 
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CHAPTER ONE: LIVER DISEASE AND INNATE IMMUNITY 
Alcoholic liver disease 
Disease spectrum and progression 
Alcohol consumption is a common event in the western world. Alcohol 
abuse or dependence, however, is responsible for 40 to 50% of all liver-related 
deaths1. Alcoholic liver disease (ALD) is used to describe the full spectrum of 
alcohol-related pathology. The spectrum of ALD can be classified into three 
categories, steatohepatitis, alcoholic hepatitis (AH), and cirrhosis2. Some patients 
with steatohepatitis progress to fibrosis, where an inflamed liver in which dead 
hepatocytes are replaced by deposition of extracellular matrix proteins, altering 
the liver’s functional ability3. Advanced fibrosis results in cirrhosis and often end-
stage liver failure. AH has a high mortality, associated with poor four-year 
survival especially in the presence of cirrhosis, ranging from 35% to 60 %. Due to 
the complexities of the disease, and the spectrum of severity displayed by 
patients with alcoholic liver disease, aspects of which remain poorly understood, 
there is still no FDA approved treatment for this disease. Corticosteroids are 
most commonly prescribed4, yet even these patients have a six-month mortality 
of 40%. These poor clinical outcomes highlight the urgent need to gain a better 
understanding of mechanism and therapeutic targets.   
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Figure 1.1 Spectrum of alcoholic liver disease 
Alcoholic liver disease is a spectrum of various ethanol-induced pathologies. 
Upon initial ethanol exposure, hepatocyte death and steatosis. Inflammation 
stems, in part, due to microbial products entering the liver through ‘leaky gut’, 
activating the immune system. Subsequent and repeated ethanol exposure can 
result in alcoholic steatohepatitis, alcoholic hepatitis, fibrosis and even cirrhosis. 
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Disease biology  
The complexity of ALD in its various stages is due to the involvement and 
dysfunction of multiple cell types and multiple organs. Although this work is 
focused entirely on the effects of ethanol on liver biology, ethanol consumption 
can have lasting effects on the brain, gut and microbiome. Within the liver, 
hepatocytes are responsible for processing of ethanol, opening the gates for 
metabolic imbalance that results in lipid accumulation in the liver, or steatosis. 
Further ethanol exposure results in the onset of inflammation, resulting in 
steatohepatitis. Inflammation itself can further increase steatotic state, recruiting 
more inflammatory cells, thus further escalating the disease and its severity. In 
this way, ethanol metabolism, directly and indirectly, damages hepatocytes and 
pushes inflammation through various innate immune pathways and crosstalk 
from cell-to-cell.  
Accumulation of ethanol-induced oxidative stress is a key mechanism for 
hepatocyte injury. Hepatocytes are well equipped in neutralizing reactive oxygen 
species through production of glutathione among others5. However, under 
chronic alcohol consumption, stores of glutathione are depleted6,7, severely 
limiting a hepatocyte’s ability to buffer against ROS. In the liver, ethanol is mainly 
metabolized via its oxidation by alcohol dehydrogenase, yielding acetaldehyde8,9. 
Acetaldehyde, its byproduct, is a highly toxic chemical10. Roughly ten percent of 
the ethanol is metabolized by cytochrome P450-2E1 (CYP2E1) in microsomes 
11,12. In this scenario, ROS and other ethanol intermediate metabolites are 
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produced, such as hydrogen peroxide and superoxide13-15, forming protein and 
DNA adducts, lead to an increase in lipid peroxidation5,16 and even create 
carcinogenic products17. The ethanol-inducible enzyme CYP2E1, expressed 
almost exclusively in zone 3 of the hepatic lobule, is used when alcohol 
dehydrogenase is saturated, thereby increasing oxygen demand and creating a 
hypoxic and ROS-susceptible microenvironment in the liver 18. The zonal 
distribution of CYP2E1 inversely correlates with oxygen gradient. In contrast, 
zone 1 near the hepatic artery, is oxygen-rich with low CYP2E1 expression19-21. 
This hepatocyte heterogeneity throughout the hepatic lobule results in a zonal 
distribution of liver injury from metabolism of ethanol and other xenobiotics like 
carbon tetrachloride and acetaminophen. This zonal distribution of liver injury 
may explain why some hepatocytes are prone to undergo apoptosis and/or 
necrosis. As explained later, hepatic gap junctions may also play a role in this 
phenomenon.  
Innate immunity overview 
TLR4 signaling 
Alcohol exposure creates intestinal permeability. This “leaky gut” allows 
bacterial lipopolysaccharide (LPS) wall fragments, also referred to as endotoxin, 
to reach the liver, an important line of defense against infection from the gut. 
Translocation of LPS to the liver triggers the innate immune system: Kupffer cells 
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(KC), the resident macrophages in the liver, recognize LPS.  KC-recognition of 
LPS requires the Toll-like receptor 4 (TLR4), which triggers two downstream 
signaling pathways. The TLR4/MyD88 pathway activates a network of cytokines, 
such as tumor necrosis factor-alpha (TNF-α), resulting in liver inflammation22. 
The TLR4/TRAM/TRIF pathway, conversely, triggers TANK-binding kinase 1 
(TBK1)-mediated interferon regulatory factor 3 (IRF3) activation23.  
The essential role of the TLR4 signaling in ALD was demonstrated in mice 
lacking functional TLR4 that showed attenuation of alcoholic steatohepatitis24,25. 
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Figure 1.2 TLR4 activation of TBK1 and IRF3  
TLR4 can be activated by gut-derived LPS. This simplified model shows the 
MyD88-independent signaling via its adaptors TRAM and TRIF. Signal 
transduction leads to activation of TBK1, the kinase responsible for IRF3 
phosphorylation and activation.  
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In previous studies, our lab reported that the MyD88-dependent pathway 
was dispensable for ALD, and observed complete protection from alcohol-
induced inflammation, steatosis and injury in mice deficient in IRF326, suggesting 
that the pathogenic effects of TLR4 in ALD were mediated via the TRAM/TRIF-
dependent pathway. However, the mechanisms by which IRF3 causes ALD 
remain obscure. 
IRF3 signaling 
IRF3 is a transcription factor that plays an important and well described 
role in response to viral infection27-31. IRF3 is in its active state when 
phosphorylated and dimerized. The eventual nuclear translocation of activated 
IRF3 leads to the production of type-I interferon (IFN) and many IFN-inducible 
genes that crate an anti-viral state. Traditionally, IRF3 activation has been shown 
to occur via TLR signaling32. However, stimulator of interferon genes (STING)-
mediated activation of IRF3 is independent of TLR signaling. Moreover, IRF3 has 
other roles in addition to its function as a transcription factor: IRF3 can promote 
apoptosis in virus-infected cells33-35. IRF3 associates with mitochondria and 
interacts with the pro-apoptotic protein BAX, leading to cytochrome c release and 
a caspase activation cascade. STING, previously referred to as transmembrane 
protein 173 (Tmem173), is an endoplasmic reticulum (ER) trans-membrane 
protein that acts as a secondary sensor to cytosolic double stranded (ds) DNA. 
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Activation of STING leads to a conformational change, which allows for TBK1 
kinase recruitment to activate IRF329. STING activation of IRF3 occurs from 
intracellular double stranded (ds) DNA, from self or pathogen, in a sequence-
independent manner36. 
There are several known intracellular dsDNA sensors that activate STING 
signaling in response to microbial infection37. The ds DNA sensor cyclic GMP-
AMP (cGAMP) synthase (cGAS)38-40, is a known activator of STING by its 
synthesis of the cyclic dinucleotide 2¢3¢-cGAMP. A different type of cyclic 
dinucleotide synthesized by bacteria, c-di-GMP, is another strong STING 
activator41,42. The bacterial cyclic dinucleotides are synthesized by diguanylate 
cyclase (DGC), an enzyme present in roughly 90% of bacteria43,44. Cyclic 
dinucleotides are hydrolyzed by a variety of phosphodiesterases, converting 
cyclic dinucleotides to GMP. The potential role of cyclic dinucleotides in ALD is 
yet to be explored.  
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Figure 1.3 Endogenous and bacterial cyclic dinucleotide activation of 
STING  
STING can be activated by cyclic dinucleotides synthesized by endogenous 
cGAS, which secretes 2’3’-cGAMP, or bacterial diguanylate cyclase, which 
secrete c-di-GMP. We hypothesize cGAS activation in hepatocytes results in 
2’3’-cGAMP-medated activation of STING. We also postulate that ethanol-
induced ‘leaky gut’ results in STING and IRF3 activation in the liver through 
microbial products like LPS and c-di-GMP.   
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Hepatic gap junctions 
A gap junction is formed by a pairing of head-to-head hemi-channels 
assembled on adjacent cells45. These channels are made of connexin (Cx) 
proteins. The nomenclature for this Cx family of proteins is based on their 
respective molecular weights. In the liver, the majority of non-parenchymal cells 
express Cx43, whereas hepatocytes express ninety-percent of all Cx32 hepatic 
expression46.  
In the event of an infection, secretion of antiviral and pro-inflammatory 
cytokines to establish an antiviral state, such as IFNβ and TNFα, may not be 
enough. Viruses have evolved strategies for limiting secretion of these cytokines 
to evade host innate immunity47. Gap junctions, by directly connecting cytosol 
from adjacent cells, allow for diffusion of ions, second messengers and 
metabolites48. However, this diffusion of information is not cargo selective and 
not context-specific.  
Even though pro-inflammatory signaling is powerful and essential in the event of 
an infection, it must be tightly regulated. Unregulated inflammation can lead to 
disease. A study showed that during acetaminophen overdose, an example of a 
sterile injury, gap junctions are responsible for the amplification of acute pro-
inflammatory signaling induced by hepatocyte damage49. Inhibition of gap-
junction communication limited the extent of the injury and protected against liver 
failure in vivo. Interestingly, in response to viral infection, cyclic dinucleotides 
were shown to spread through gap junctions50. More specifically, gap junctions 
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allow for the spread of DNA-mediated cell-to-cell activation of IRF351. Cyclic 
dinucleotide communication through gap junctions triggers STING and IRF3 
activation in neighboring cells, thus amplifying the anti-microbial response. Given 
the zonal distribution of hepatocyte damage in alcoholic liver disease, we 
hypothesize that activation of IRF3 via gap junction-mediated cyclic dinucleotide 
contributes to amplification of cell death and inflammation in ALD.  
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Figure 1.4 Proposed propagation of cyclic dinucleotides through hepatic 
gap junctions in ALD  
Gap junctions allow the cell-to-cell transfer of cyclic nucleotides synthesized by 
cGAS This leads to an amplification of STING activation to neighboring cells, and 
a pro-apoptotic and pro-inflammatory signaling cascade.   
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Programmed cell death 
Cell death can present itself in a variety of ways. Necrosis and osmotic 
lysis are examples of unregulated, un-programmed cell death, resulting in LDH 
and DAMP release, and propidium iodide-positive staining. Programmed cell 
death depends on signal transduction pathways that eventually result in cell 
death. Apoptosis is a regulated, programmed cell death that results in ATP 
depletion, Annexin V-positive staining, and is ‘clean’ in nature, with no DAMP 
release – usually terminated by phagocytosis52,53. In the event that phagocytosis 
does not remove cell debris, secondary necrosis (also commonly referred to as 
late apoptosis) will ensue54. On the other hand, inflammasome-mediated 
pyroptosis and RIP1-mediated necroptosis are two forms of programmed cell 
death which result in a necrotic form of cell death55-57.  
Apoptosis in hepatocytes results from displacement or down-regulation of the 
Bcl-2 family of anti-apoptotic proteins and subsequent activation of pro-apoptotic 
BH3-only proteins such as BAX and BAK58-61. These events lead to 
oligomerization of BAX and BAK, resulting in permeabilization of the outer 
mitochondrial membrane and execution of the intrinsic apoptotic process62. 
Recently, IRF3, a transcription factor that induces IFN-β, has been shown to play 
a major role in cell death by way of its newly characterized BH3-only domain. 
IRF3 associated with the pro-apoptotic adaptor BAX and triggered apoptosis in 
murine embryonic fibroblasts and murine hepatocytes34,35. However, it is not 
known whether other key signal transduction events in hepatocytes are required 
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for the pathogenesis of fibrosis and ALD. However, the liver is capable of 
regeneration, leading to rapid repopulation of the organ through stem cell 
differentiation into immature hepatocytes.  
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Figure 1.5 Apoptotic signaling via BH3-mediated association of IRF3 with 
BAX  
Upon phosphorylation, IRF3 dimerizes and translocate to the nucleus, leading to 
type-I IFN induction. Under certain conditions, IRF3 co-localizes with BAX on the 
mitochondrial membrane through their BH3 motifs. This allows for activation of 
pro-apoptotic BAX, resulting in mitochondrial apoptosis through Caspase-8 and 
Caspase-3 cleavage.   
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The Inflammasome 
Progression of ALD to an advanced stage is tightly linked to liver 
inflammation63. Our lab previously demonstrated that the pro-inflammatory 
cytokine, interleukin (IL)-1β is required for the development of alcohol-induced 
liver inflammation, steatosis and injury and that the pathogenic effect of IL-1β is 
specific to resident liver macrophages64. We also demonstrated that in the mouse 
model of ALD, the conversion of inactive pro-IL-1β to active IL-1β required the 
inflammasome, an intracellular multicomponent complex that triggers 
inflammation in response to endogenous danger signals. The inflammasome 
relies on pattern-recognition receptors (PPRs), such as TLRs and NOD-like 
receptors (NLRs)65 through the two-step process for active IL-1β synthesis. In the 
first step, microbial-derived signals upregulate pro-IL-1b mRNA, resulting in 
synthesis of inactive pro-IL-1β. This step is triggered by binding of bacterial LPS, 
derived from the gut, to the TLR4 on Kupffer cells, and provides an initial pro-
inflammatory signal in ALD25,66-69. Deficiency in TLR4 prevents upregulation of 
pro-IL-1b mRNA in the liver of alcohol-fed mice70. In the second step, a variety of 
damage-associated molecular patterns (DAMPs) or ‘danger signals’ derived from 
host cells activate the inflammasome, resulting in cleavage of pro-IL-1β into the 
active IL-1β71. The nature of endogenous DAMPs that activate inflammasome 
and IL-1β in ALD were not previously known. 
We show that hepatocytes damaged by ethanol release the endogenous 
metabolic danger molecules, uric acid and ATP, which are recognized by liver 
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immune cells as inflammatory signals. Uric acid and ATP from damaged 
hepatocytes are required for processing and activation of IL-1β, a cytokine 
requiring inflammasome activation that is crucial in the pathogenesis of ALD. Our 
data suggests that the release of these molecules represent signals permissive 
for the pro-inflammatory effect of LPS in ALD.  
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Figure 1.6 Two-signal activation of inflammasome signaling 
The NLRP3 inflammasome is a tightly-regulated inflammatory complex, activated 
through a two-signal system, relying on PAMPs and DAMPs. The first signal 
comes from exogenous gut-derived LPS, serving as a priming step. The second 
signal acts on NLRP3, can have many sources. In ALD, ATP and uric acid are 
endogenous DAMPs from damaged hepatocytes that activate NLRP3, resulting 
in cleavage and maturation of IL-1β.  
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Inflammation as a driver for ALD 
Although hepatocyte damage from ethanol exposure is the first event 
observed in early ALD, inflammation through IL-1 and other cytokines plays a 
potentially bigger role in adding to its severity and complexity. The liver is an 
organ made up of 15-20% non-parenchymal cells, many of which are immune 
cells.  
Increased levels of circulating LPS can be detected in humans and mice 
after chronic ethanol consumption, correlating with the severity of the disease72-
76. Interestingly, binge drinking also results in an increase in circulating LPS and 
other pathogen-associated molecular patterns (PAMPs)69. In addition to signaling 
through IRF3, TLR4-mediated signaling provokes a strong inflammatory 
response through MyD88-dependent and independent pathways. These 
branching signal transduction pathways result in activation of mitogen-associated 
kinases ERK and JNK, as well as in NFκB, TNFα  and IL-6 release77,78. 
Hepatocytes are particularly susceptible to TNF-mediated cell death through a 
priming effect from chronic ethanol exposure79-81. Further adding to this 
potentiation of hepatocyte death, ethanol exposure has been shown to increase 
expression of TNFα-receptor 59. Lastly, monocyte chemoattractrant protein 1 
(MCP1) has been identified as an important cytokine in ALD, due to its dual role 
in recruiting more inflammatory cells to the liver as well as inducing steatosis82-84.  
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Current treatments 
A recent multi-center clinical trial (Cleveland Clinic, University of Louisville, 
UT Southwestern, and University of Massachusetts Medical School) aims to 
target inflammasome signaling in the treatment of severe alcoholic hepatitis. In 
addition of the standard of care, patients with severe alcoholic hepatitis will be 
administered a combination of Anakinra, an IL-1R antagonist64, pentoxifylline, a 
phosphodiesterase inhibitor that suppresses TNF-α signaling85,86, and zinc which 
attenuates gut barrier permeability87-89. The goal of this multifaceted approach 
aims for a differential targeted approach at various components involved in the 
activation and escalation of IL-1 signal transduction, starting with gut-derived 
LPS, along with IL-1R and TNF-α -mediated amplification of inflammation.  
 
Mouse models of ALD 
Dynamic manipulation of organs and cells and components within as they 
respond to ethanol exposure, as well as accessing these samples for 
biochemical studies, is only possible by the use of in vivo and in vitro models. For 
in vivo studies, there are various approaches used to study specific 
characteristics within the spectrum of alcoholic liver disease, ranging from acute 
exposure, to more complex events associated with chronic ethanol consumption, 
as well as acute-on-chronic ethanol injury, an amalgam of the latter two. We 
generally use female mice, due to their increased susceptibility to ethanol-
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induced liver damage, in the range of six-to-eight weeks of age. Whenever 
possible, C57BL/6 mice are used as WT strain, although we always matched the 
background genotype of our knockout mice for every experiment. The C57BL/6 
mice is the best for ad libitum feedings, since they offer the least resistance to 
ethanol compared to other strains.  
Acute Ethanol Binge 
In order to study the early events associated with acute ethanol 
administration in vivo, an ethanol binge is administrated. We have used a 
standard dose given as a bolus at a dose of 5 g/kg using a gavage needle with 
ball tip. The control group receives a maltodextrin gavage at a dose of 9 g/kg. We 
found the ideal time-point for peak phosphorylation of IRF3 and cleavage of 
Caspase-1 is when mice are sacrificed 4 hours after binge. However, liver injury 
as measured by serum ALT peaks at 8 or 9 hours post binge. It is therefore 
important to tailor time-points for sacrifice to each specific readout as required by 
the experiment. 
Chronic Ethanol Administration 
The standard method for chronic ethanol administration ad libitum to WT 
mice in the field of gastroenterology is using the Lieber-DeCarli method90,91. This 
involved a ramp-up stage when mice are first exposed to control liquid diet on the 
first day along with chow. On the following day, chow diet is removed (0% 
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ethanol). The next day, Lieber-DeCarli diet with 1% ethanol is introduced, with an 
increase in one percent every subsequent day until reaching 5%. The first day 
with 5% ethanol is counted as the first full day of the ethanol feeding until 
reaching 4 weeks. There are variations of this feeding which can be extended for 
6 weeks or shortened as needed. Regardless of the length of the feeding, the 
control group is given a Pair-fed diet where the calories are adjusted every day 
based on daily consumption changes in the ethanol group. The food is prepared 
fresh daily for both groups. The ethanol group has to have its calories 
supplemented with maltodextrin so that the ethanol and sugar always combine to 
a total of 355 kcal/liter. This adjustment is especially important during the ramp-
up phase, when the amount of ethanol is changed daily but the number of 
calories remain the same.  
Acute-on-chronic Ethanol Administration 
Often with patients with alcoholic liver disease, the phenotype associated 
when present at the clinic is one of complexity associated with years of chronic 
ethanol consumption compounded with acute binging, resulting in a rapid 
inflammatory response and followed with deterioration of their condition. To best 
mimic this phenotype, the standard four week ethanol feeding has been adjusted 
to a ten day chronic ethanol feeding with a single binge at the end92. In this 
model, mice are typically sacrificed 9 hours post binge, when peak liver injury is 
observed, but we tailored this to meet our needs depending on the experiment. 
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This model entails the use of 5% ethanol on day 1, without the incorporation of a 
ramp-up phase. The timing of this model results in the benefit of being a 
shortened period as well as increased liver injury and inflammation, highlighted 
by the presence of increased neutrophil infiltration to the liver – a cell-type not 
present in large numbers during a four-week ethanol feeding.  
We also modified this model when trying to achieve a type of injury and 
inflammation greater than that observed with just ten days and a single binge. To 
best mimic acute AH, we administered a 4 week Lieber-DeCarli ethanol diet, and 
administered 3 ethanol binges during the final 3 days of the feeding93.  
Moreover, as part of that study, we used this model of intense acute-on-chronic 
ethanol challenge to study the dynamics, over a period of seven days, of 
recovery from ethanol-diet withdrawal. During that time, we observed hepatocyte 
ballooning, liver infiltration by neutrophils days after the final ethanol dose, 
followed by impaired hepatocyte regeneration – characteristics previously 
unidentified in animal models of ALD yet important components of the disease in 
humans.   
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Figure 1.7 Mouse models of alcoholic liver disease 
To model different characteristics of ALD in mice, we use different approaches 
for ethanol administration. The NIAAA acute-on-chronic model relies on 10 days 
of 5 % ethanol ad libitum feeding. On the tenth day, an ethanol binge is 
administered, and mice are sacrificed typically 9 hours post binge (A). The 
traditional 4-week ethanol feeding ad libitum feeding incorporates a 5-day ramp-
up period starting with 1% ethanol, escalating one-percent per day until reaching 
5% ethanol, referred to as day 1 (B). A model of alcoholic hepatitis, this amalgam 
of the acute-on-chronic and traditional 4 week ethanol feedings, results in 
extensive inflammation and liver injury (C). These feedings rely on Lieber-DeCarli 
diet, with iso-caloric or ‘pair-fed’ controls.  
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Other Mouse Models of Liver Injury 
Fibrosis 
Fibrosis represents a late-stage of liver disease that is common to all 
chronic liver diseases including viral hepatitis, alcoholic and non-alcoholic fatty 
liver disease, biliary liver diseases, and some genetic liver diseases. In spite of 
their specific etiologies, common denominators of fibrosis are shared among all 
these liver diseases, including liver inflammation and hepatocyte death. 
Fibrosis results from chronic unresolved liver inflammation and may 
progress from fibrotic scarring to cirrhosis that ultimately leads to liver failure. 
Inflammation triggers liver fibrosis via a signaling event in which Kupffer cells 
activate hepatic stellate cells (HSC) to deposit collagen94,95. Liver dysfunction 
results from the fibrotic tissue distorting the liver parenchyma. This process 
involves a dynamic and complex series of multicellular events, involving 
inflammation and HSC activation. The hepatocyte is primarily responsible for 
metabolism and detoxification, and as such, it is often exposed to damage due to 
toxic metabolites and reactive oxygen species. However, the role of hepatocyte 
death in liver fibrosis has been only partially elucidated. Data available up to date 
demonstrate that hepatocyte apoptosis activates HSC via paracrine 
mechanisms. Alternatively, HSC can be directly activated by apoptotic bodies96.  
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Induction of fibrosis through carbon-tetrachloride 
We used carbon-tetrachloride (CCl4), a chemical that, in the short term, 
induces hepatocyte apoptosis97, which is followed by secondary necrosis98. CCl4 
is metabolized by CYP2E1, therefore the resulting phenotype bears many 
similarities with ethanol-induced liver injury. When administered repetitively, CCl4 
induces liver fibrosis99. Using two models of CCl4-induced liver injury, we 
investigated the complex multi-cellular events associated with fibrosis in a 
chronic model, as well as the tightly-controlled signal transduction events 
associated with early disruption of homeostasis and cell death in the acute 
model. 
Acetaminophen-induced acute liver failure 
Acetaminophen (APAP) overdose is one of the leading causes of acute 
liver failure, lead by a signaling cascade triggered by hepatocyte death and liver 
inflammation. Interestingly, APAP overdose results in hepatocellular damage that 
propagates even after the concentration  of  circulating  xenobiotic  has  declined  
to  unmeasurable  levels100. This suggests a potential role for propagation of 
preexisting injury, rather than simply de novo direct injury. 
Much like ethanol-induced liver injury, APAP pathogenesis exhibits spatial 
heterogeneity, due in part to varying expression levels of CYP2E1101-104. This 
zonation of APAP-induced injury occurs during the initial phase of injury105, 
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resembling an exaggerated phenotype observed with ethanol and CCl4 
administration. The second phase of injury is poorly defined, however106. In this 
model, mice are starved 15 hours (overnight) before a single intraperitoneal 
APAP administration. The removal of food allows for glutathione depletion, 
exacerbating liver injury. A dose of 500 mg/kg is a commonly used lethal dose 
over the course of 24 hours.  
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CHAPTER TWO: IRF3 SIGNALING IN ALD 
IRF3 is required for the development of ALD in mice 26, but the 
mechanisms underlying its pathogenic role in the liver are not known. To gain a 
better insight into its pathology, we investigated mechanisms upstream and 
downstream of IRF3 phosphorylation in various models of ALD, initially focusing 
on the early events after ethanol exposure as a simplified model. 
Results 
Pathogenic role of IRF3 in ALD 
We first tested the phenotype of whole-body IRF3-knockout (KO) mice 
after a 4 week Lieber-DeCarli chronic ethanol feeding. IRF3-KO mice showed full 
protection from ethanol-induced liver damage, compared to WT ethanol-fed mice 
(Fig. 2.1A). Consistent with its role in induction of TNF-α 107, an absence of IRF3 
signaling led to a protection from liver inflammation compared to WT mice, as 
seen by no increase in expression of pro-inflammatory genes Tnfa, pro-IL1b and 
Mcp1 mRNA(Fig. 2.1B). However, IRF3-KO mice had a similar increase to WT 
mice in serum endotoxin (Fig. 2.1C). We chose the 4-week Lieber DeCarli model 
because as the standard chronic ALD model, it would reveal if IRF3 played any 
role in its pathogenesis. Together, this data suggested that ethanol-induced liver 
injury and inflammation in this model was driven by IRF3 signaling, but not 
determined entirely by levels of circulating lipopolysaccharide.  
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Figure 2.1. Profile of chronic ethanol injury in WT and IRF3-KO mice  
A 4 week Lieber-DeCarli ethanol diet was administered to WT and IRF3-KO 
mice. Blood and liver tissue were isolated. Liver injury was evaluated using 
serum ALT (A); Liver inflammation was measured from expression of Tnfα, pro-
IL1β, and Mcp1 mRNA using RT-PCR (B); Bacterial lipopolysaccharide 
(endotoxin) was measured from serum (C) . n = 6-10 mice per group. * P < 0.05 
vs baseline. 
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The 4-week model of ALD represents a compound outcome of both acute 
and chronic events. We sought to understand the dynamics of liver injury and 
phosphorylation of IRF3 after initial ethanol exposure. For this, we used the 
ethanol binge model, where WT mice were given an oral bolus of 5 g/kg ethanol 
or iso-caloric maltodextrin. Mice were sacrificed at various time-points, as 
indicated. We detected a rapid increase in serum endotoxin, as early as 1 hour, 
peaking at 2 hours, and normalizing 8 hours after the ethanol binge (Fig. 2.2A). 
Liver injury, as measured by serum ALT, followed a gradual increase peaking at 
8 hours after the binge, which then normalized by hour 16 of the experiment (Fig. 
2.2A). During this time-course experiment, we detected no increase in liver 
expression of pro-inflammatory Tnfa mRNA (Fig. 2.2A), which supported our 
findings from chronic feeding (Fig. 1.2B). We did, however, detect an early 
increase in Ifnb liver mRNA, as early as 2 hours, peaking 4 hours after ethanol 
administration. INF-β, a type-I IFN, is induced upon IRF3 phosphorylation and 
translocation to the nucleus. This early increase in Ifnb mRNA suggested early 
involvement of IRF3 in a single-binge ethanol-induced liver injury model.  
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Figure 2.2. Profile of acute ethanol injury and inflammation in WT mice  
A single dose of EtOH (5 g/kg) was administered to WT. Blood and liver tissue 
were isolated at indicated time points. Liver injury was evaluated using serum 
ALT (A, right in red); Bacterial lipopolysaccharide (endotoxin) was measured 
from serum (A, left in blue). Liver inflammation was measured from expression of 
Ifnb and Tnfα was measured from liver lysate using RT-PCR (B).  n = 5-8 mice 
per group. * P < 0.05 vs baseline. 
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Early ALD is a hepatocyte-driven phenotype 
We directly tested whether Kupffer cells were responsible for this early 
damage from ethanol administration. We depleted resident macrophages from 
the liver via clodronate injection, which we confirmed two days later via F4/80 
immunohistochemistry (Fig. 2.3A). Depletion of Kupffer cells by clodronate did 
not affect liver injury assessed by ALT levels (Fig. 2.3B). As noted earlier, acute 
liver injury induced by a single dose of ethanol was not accompanied by 
inflammation (Fig. 2.1B). Here, we found that initial liver injury developed 
independent of Kupffer cells, a major source of inflammatory cytokines in the 
liver. We then tested if IRF3 was needed for liver injury in a single ethanol binge, 
to help isolate the early events from ethanol exposure from the more intricate 
associated with the chronic disease that involve recruitment of more immune 
cells to the liver. We compared WT mice and IRF3-KO mice to mice deficient in 
inflammatory signaling. The extent of protection from liver damage in IRF3-KO 
mice was superior to that observed in other strains deficient in innate immune 
signaling. For example, absence of inflammasome components, Caspase-1 
(Casp-1) which is required for IL-1β maturation, or inhibition if IL-1R with IL-1R 
antagonist (IL-1Ra, also known as Anakinra) 64, surprisingly did not protect from 
liver injury (Fig. 2.3C). This data suggested that acute alcoholic liver injury is 
dependent on IRF3, but independent of Kupffer cells and inflammation. 
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Figure 2.3   Acute liver injury develops independently of liver immune cells  
WT mice received i.v. clodronate or PBS (control). Two days later, depletion of 
immune cells was verified by histology of liver sections through F4/80 
immunostaining (A). A single dose of EtOH (5 g/kg) was administered to WT 
mice previously treated with clodronate or PBS. Blood was isolated at indicated 
times and liver injury was evaluated by serum ALT (B).  A single dose of EtOH (5 
g/kg) was administered to WT, Caspase-1 (Casp1)-KO, IRF3-KO, and mice pre-
treated with IL-1Ra (Anakinra). Blood was isolated at indicated times and liver 
injury was evaluated by serum ALT. (C) n = 5 mice per group. * P < 0.05 vs 
baseline.   
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Phosphorylation dynamics 
We had established a critical pathogenic role for IRF3 in the liver upon 
ethanol-induced injury. We previously identified that a single binge had resulted 
in an Infb mRNA increase, suggestive of IRF3 activation. However, we did not 
know if involvement of IRF3 in ALD involved its phosphorylation and activation. 
We tested dynamics of IRF3 phosphorylation in total liver in WT mice – and for 
that, we needed to perform ethanol exposure to a single binge over various time 
points. We detected rapid phosphorylation in liver after an ethanol binge at 1 
hour. This signal remained elevated up to 8 hours, after which it decreased back 
to baseline (Fig. 2.4A-B). Given the early induction of Infb mRNA, as well as 
subsequent liver injury within the first hour, we hypothesized that IRF3 
phosphorylation would occur in hepatocytes. To test this, we administered an 
ethanol gavage to WT mice, isolated hepatocytes through liver perfusion 2 hours 
later. We detected an increase in phosphorylated IRF3 in these hepatocytes 
(Fig. 2.4C-D). We found a similar dynamic of IFN-β production as that previously 
observed with Infb mRNA (Fig. 2.4E).  
This was the first reported case of IRF3 phosphorylation in hepatocytes, a 
previously well-studied player of innate immunity in immune cells. We confirmed 
IRF3 protein expression in primary murine hepatocytes (Fig. 2.4F). I will use this 
opportunity to show relative levels of other important signaling components in the 
IRF3 signaling axis, cGAS and STING, which are all expressed by WT C57BL/6 
mice.  
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It is important to highlight a recent publication that stated there was no 
detectable STING protein expression in WT primary murine hepatocytes108. It 
should be noted, however, that this publication does show increased STING 
protein expression in murine liver lysate compared to STINGGt/Gt mice, a 
genotype with deficient STING signaling first identified in a mutational screen109. 
This report did detect expression of cGAS and IRF3 in primary murine 
hepatocytes.  
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Figure 2.4 IRF3 is activated in hepatocytes after acute ethanol in vivo  
One dose of EtOH (5 g/kg) was administered in vivo to WT mice. Livers were 
isolated at indicated time points and whole-cell lysate was probed for 
phosphorylated IRF3 (p-IRF3) and total IRF3 via western blot (A). Densitometry 
was calculated using ImageJ (B). Two hours after a binge, hepatocytes were 
isolated from the liver. Phosphorylated IRF3 and total IRF3 were analyzed by 
western blot (C). n = 3 mice per group. Densitometry was calculated using 
ImageJ. (D). Serum was isolated and serum IFN-β was measured by ELISA (E).  
n = 5-8 mice per group. Hepatocytes were isolated from livers of WT, cGAS-KO, 
STING-KO, and IRF3-KO six to ten week-old female mice, all on C57BL/6 
background. Protein expression of cGAS, STING and IRF3 in hepatocytes was 
assessed via western blot (F). * P < 0.05 vs baseline  
 67 
 
   
60
Primary murine 
hepatocytes
β-Tubulin
50
40p-IRF3
total IRF3
50
Sugar
50
40
1x  EtOH
 in vivo
Densitometry:
p-IRF3/IRF3
Control EtOH
0
10
20
30
40
fo
ld
-in
cr
ea
se
  <0.001
C D E
Immunoblotting
0     1     2    4      8    16 hrs
p-IRF3
total IRF3
β-tubulin
50
40
60
50
50
40
A
p-
IR
F3
/ t
ot
al
 IR
F3
fo
ld
-in
cr
ea
se
0 1 2 4 8 16
0
1
2
3
4
5
*
*
**
hours
densitometryB
pg
/m
L
0 1 2 4 8 16
0
1
2
3
4
5
*
* *
hours
serum IFN-β
Primary murine 
hepatocytesF
 68 
Pathogenic effect of IRF3 independent of TRAM and IFNAR 
We asked whether the pathogenic role of IRF3 in ALD was mediated by its 
upstream activator TRAM, the MyD88-independent adaptor which bridges TLR4 
with downstream signaling that induces phosphorylation of IRF3 in immune 
cells23. Interestingly, no protection from alcohol-induced liver inflammation or 
alcohol-induced acute or chronic liver injury or inflammation was observed in 
mice deficient in TRAM (Fig. 2.5A-C). We also found no protection in these mice 
from acute ethanol-induced liver injury compared to the WT group (Fig. 2.5D). 
We found a similar lack of protection in mice deficient in either TLR4 or TRIF, 
another MyD88-independent adaptor110.  Since pathogenicity seemed driven by 
IRF3 and not upstream activators, we tested downstream signaling of IRF3. We 
found that deficiency of the type-I IFN receptor (IFNAR1) failed to provide 
protection from acute or chronic alcohol-induced liver injury and inflammation 
(Fig. 2.5E and 110). There was no protection from ALD in mice deficient in 
IRF7110, a type-I IFN-inducing transcription factor distinct from IRF323. 
Collectively, these findings demonstrated that IRF3 determines pathology in the 
early stage of ALD, independently of inflammation or type-I IFN signaling. Our 
data also suggested that the signal for activation of IRF3-dependent ALD in the 
early phase of alcohol-induced liver injury was not mediated by TLR4 or its 
adaptor TRAM. 
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Figure 2.5 Liver injury is independent of TRAM and IFNAR signaling in ALD  
A 4 week Lieber-DeCarli ethanol diet was administered to WT and TRAM-KO 
mice. Blood and liver tissue were isolated. Liver injury was evaluated using liver 
histology with H&E staining (A), and serum ALT (B); Liver inflammation was 
measured from expression of Tnfa mRNA using RT-PCR (C); n = 6-10 mice per 
group. A single dose of EtOH (5 g/kg) was administered to WT or TRAM-KO 
mice. Blood was isolated at indicated times and liver injury was evaluated by 
serum ALT (D).  A single dose of EtOH (5 g/kg) was administered to WT or 
IFNAR1-KO mice. Blood was isolated at indicated times and liver injury was 
evaluated by serum ALT (E). * P < 0.05 vs baseline. # P < 0.05 vs TRAM-KO 
baseline. 
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Association with mitochondria 
In trying to gain a better understanding of the pathogenic role of IRF3, we 
focused on the recently described pro-apoptotic role of IRF334,35. We 
hypothesized that IRF3 partners with BAX to translocate to the mitochondria and 
initiate apoptosis of hepatocytes.  
Phosphorylation of IRF3 in the liver occurred early after a single 
intragastric dose of alcohol (Fig. 2.4A), which preceded the development of 
significant liver injury. This was accompanied by cleavage of caspases 8 and 3, 
suggestive of apoptosis in the liver (Fig. 2.6A,B). Notably, we found that 
following ethanol administration, IRF3 associated with the apoptosis-initiating 
caspase 8 and with the mitochondria-permeabilizing protein BAX in the liver (Fig. 
2.6C,D). Together, these data demonstrated that early after administration of 
ethanol, IRF3 is activated and interacts with the apoptotic signaling pathway in 
the liver, leading us to hypothesize that IRF3 regulates apoptosis in hepatocytes.  
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Figure 2.6 IRF3 induces apoptotic signaling through association with BAX 
in early ALD  
One dose of EtOH (5 g/kg) was administered in vivo to WT mice. Livers were 
isolated at indicated time points and whole-cell lysate was probed for cleaved 
Caspase-8 and cleaved Caspase-3 via western blot (A). Densitometry was 
calculated using ImageJ (B). Immunoprecipitation performed of IRF3 in whole-
cell liver lysate at indicated time-points, and probed for associated with Caspase-
8 p43 fragment and BAX (C). Densitometry was calculated using ImageJ (D). n = 
3 mice per group. * P < 0.05 vs baseline  
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We further investigated whether IRF3 was required for hepatocyte 
apoptosis using the Fas-activating Jo2 antibody. Hepatocytes have a 
pronounced susceptibility to Fas-mediated apoptosis. We found that 
administration of Fas-activating Jo2 in WT mice resulted in early phosphorylation 
of IRF3 in the liver followed by apoptosis (Fig. 2.7A,B) and liver injury (Fig. 
2.7C). When Jo2 was injected in IRF3-KO and WT mice, IRF3-KO mice were 
completely protected from liver injury and death compared to WT mice (Fig. 
2.7C,D). Specifically, compared to IRF3-KO mice, WT mice had elevated serum 
ALT (Fig. 2.7C), decreased survival (Fig. 2.7D), and increased pro-apoptotic 
signaling in the liver, as measured by cleavage of Caspase-8, -3, and Poly(ADP-
ribose) polymerase (PARP) (Fig. 2.7E). Active Caspase-3 and Caspase-7 lead to 
cleavage of PARP, an enzyme with nuclear activity in response to DNA strand 
breaks111,112.  
Collectively, this data demonstrated that IRF3 is expressed in hepatocytes and is 
required for hepatocyte apoptosis in response to ethanol. Our results 
demonstrate that the pathogenic effect of IRF3 in acute and chronic ALD is 
mediated by intrinsic IRF3-dependent hepatocyte apoptosis and is independent 
of the role of IRF3 in inflammatory or type-I IFN responses. 
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Figure 2.7 IRF3 is required for apoptosis in the liver  
One dose of Jo2 antibody 0.5 mg/kg, i.p. was administered to WT mice. Livers 
were isolated at indicated time points and whole-cell lysate was probed for 
phosphorylated IRF3 (p-IRF3), total IRF3 and cleaved PARP via western blot (A). 
Densitometry was calculated using ImageJ (B). n=3 per time-point. * and # P < 
0.05 vs baseline. One injection of Jo2 antibody (FasL) was administered to WT 
and IRF3-KO mice. Liver injury was assessed via serum ALT at 8 hours (C). 
Some mice were evaluated for survival over 48 hours (D). n= 24 (WT), n=13 
(IRF3-KO). Other mice were sacrificed 8 hours post injection. Whole-cell liver 
lysates were evaluated for cleaved PARP, cleaved Caspase-3, and cleaved 
Caspase-8 via western blot (E). n = 3-5 mice per group.   
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STING activation 
Next, we sought to identify the mechanism of IRF3 activation in ALD. 
Based on our previous observations, we hypothesized that a TRAM-independent 
mechanism was responsible for IRF3 activation in ALD. Although administration 
of Jo2 induced phosphorylation of IRF3 in the liver, we rejected the hypothesis 
that Fas signaling would be a major source of early IRF3 activation in ALD 
because significant upregulation of FasL in the liver occurred late after ethanol 
administration. 
Analysis of the subcellular baseline distribution of IRF3 in the livers of 
control WT mice revealed that IRF3 was present not only in the cytoplasmic 
fraction, but also in mitochondrial and ER extracts (Fig. 2.8A). To study the 
functional significance of this finding, we analyzed the subcellular localization of 
IRF3 after a single dose of ethanol, and found that phosphorylation of IRF3 was 
detected in the whole-cell liver extract (Fig. 2.8B), nucleus (Fig. 2.8C), ER (Fig. 
2.8D) and mitochondria (Fig. 2.8E). The western blot for total IRF3 in the ER and 
mitochondrial extracts showed a double band, which was due to the presence of 
phosphor-IRF3, which was first probed for on the same membrane. In instances 
like these, phosphor-IRF3 is the top band, while total IRF3 is below. The 
presence of phospho-IRF3 in the nucleus was consistent with the transcriptional 
role of activated IRF3107 and the early alcohol-induced Ifnb (Fig. 2.2B). 
Interestingly, the strength of the Tata-binding protein (TBP) in the nuclear extract 
decreased at 8 hours (Fig. 2.2C). The presence of phospho-IRF3 in the 
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mitochondria further supported the involvement of IRF3 in the mitochondrial 
pathway of hepatocyte apoptosis (Figs. 2.6 and 2.7).  
The finding of phospho-IRF3 in the liver ER (Fig. 2.8D) was unexpected and 
prompted us to search for potential implications of this phenomenon. It has been 
reported that ER serves as a platform for activation of IRF3 by cytosolic RNA or 
DNA of viral origin34,35, and that during certain viral infections, IRF3 associates 
with ER via binding to Stimulator of IFN gene (STING, also known as TMEM173 
or MPYS), an adaptor molecule residing in the ER membrane29. To explore 
whether interaction between IRF3 and STING occurred in the liver, we performed 
immunoprecipitation and found that following administration of ethanol, IRF3 
associated with STING in the whole-cell liver lysate (Fig. 2.8F) and in the ER 
extract (Fig. 2.8D). IRF3 also bound to phospho-TBK1 (Fig. 2.8F,H), which is a 
kinase required for IRF3 phosphorylation29. Notably, the association of IRF3 with 
STING or p-TBK1in the ER occurred rapidly after alcohol administration, at the 
same time point as the binding of IRF3 to BAX (Fig. 2.6C). Interestingly, although 
STING is also present in the outer mitochondrial membrane113, we did not see 
any association between IRF3 and STING or TBK1 in the liver mitochondrial 
fraction (Fig. 2.8G).   
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Figure 2.8 IRF3 associates with STING in the hepatic ER after acute ethanol  
Unstimulated livers from WT mice were isolated and were probed for IRF3 in 
whole-cell, cytoplasmic, mitochondrial, ER, and nuclear extracts via western blot. 
β-tubulin, porin, GRP78, and TBP were used as loading controls for cytoplasmic, 
mitochondrial, ER, and nuclear fractions, respectively (A). WT mice received a 
single dose of ethanol. At indicated time-points, presence of phosphorylated 
IRF3 (p-IRF3) protein was assessed in whole-cell, nuclear, ER and mitochondrial 
extracts (B-E). WT mice received a single dose of ethanol. At indicated time-
points, IRF3 from whole-cell, mitochondrial, and ER fractions was 
immunoprecipitated and probed for associated with phospho-TBK1 and STING 
(F-H). n=3 mice per time-point. * P < 0.05 vs baseline.  
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The presence of IRF3 in the ER upon ethanol administration, and its 
connection with STING suggested a galvanizing link through this association. To 
test this, we used Tmem173gt mice deficient in STING signaling109. We found that 
Tmem173gt mice were susceptible to chronic ethanol administration by day 28 (4 
weeks), but had decreased levels of liver injury at day 14 compared to their WT 
controls (Fig. 2.9A). We tested if this early protection could be replicated with the 
acute ethanol binge model. Indeed, Tmem173gt mice had decreased liver injury 
compared to WT mice (Fig. 2.9B). We tested if this slight protection in liver injury 
in Tmem173gt mice was mediated by IRF3. We found Tmem173gt mice had no 
detectable levels of ethanol-induced IRF3 phosphorylation and Caspase-3 
cleavage after 2 weeks of Lieber-DeCarli ethanol feeding (Fig. 2.9C,D).  
We hypothesize that the liver injury observed in the Tmem173gt mice at 4 weeks, 
equal to their WT counterparts, may be due to activation of TLR4 signaling. 
These overlapping pathways involved in IRF3 activation may be able to 
compensate over the course of a chronic injury. The involvement of TLR4 in ALD 
has been well documents by others24, in a 4 week model which was described by 
the study’s authors as early ALD. Here, we describe early ALD as earlier events. 
Additionally, it is possible that the lack of protection from late alcohol liver 
damage in Tmem173gt mice was attributable to the upregulation of inflammatory 
cytokines, which have not been reported to be controlled by STING-dependent 
signaling. Finally, these findings demonstrated that early after ethanol 
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administration, IRF3 interacts with the adaptor STING in the ER, and raised the 
question of whether ER stress was a trigger for IRF3 phosphorylation in ALD.  
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Figure 2.9 STING activates pro-apoptotic IRF3 in early ALD  
WT and Tmem173gt mice were fed an ethanol Lieber-DeCarli diet for 4 weeks. 
Liver injury was assessed by serum ALT at day 14 and day 28 (A). WT and 
Tmem173gt mice received a single dose of ethanol. At indicated time-points, liver 
injury was assessed by serum ALT (B). WT and Tmem173gt mice were fed an 
ethanol Lieber-DeCarli diet for 2 weeks. Presence of phosphorylated IRF3 (p-
IRF3) (C) and cleaved Caspase-3 protein was assessed in whole-cell liver lysate 
(C,D). n=5-9 mice per time-point. * P < 0.05 vs baseline.  
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Activation of IRF3 via ER stress 
A broad variety of stressors perturb ER function in ALD, including oxygen 
deprivation, dysregulation of calcium signaling and accumulation of misfolded 
proteins114. Disruption of intracellular homeostasis can lead to an accumulation of 
misfolded proteins associated with the unfolded protein response (UPR) in the 
ER, also known as ER stress. Excessive ER stress is associated with pro-
apoptotic signaling and can be pathogenic115,116. These events initiate 
homeostatic responses but also contribute to liver pathology117.  
ER stress triggers STING activation  
We used upregulation of Xbp1 mRNA splicing (sXbp1), a marker of early 
ER stress 118,119. We found that administration of a single dose of ethanol 
induced early ER stress in the liver, as demonstrated by increased splicing of 
Xbp1 mRNA (sXbp1) (Fig. 2.10A), a component of the ER stress-associated 
response120. Analysis of cell populations in the liver demonstrated that increased 
splicing of Xbp1 occurred in hepatocytes, but not in LMNCs of mice exposed to 
acute alcohol (Fig. 2.10B), which was consistent with the dominant role of 
hepatocytes in the metabolism of ethanol. In fact, when primary hepatocytes 
were stimulated with ethanol, the observed ER stress occurred independently of 
acetaldehyde. This finding was consistent with the findings from others that the 
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pathogenic effects from ethanol are mediated by CYP2E1 independently of 
acetaldehyde, which are themselves enhanced by LPS and TNFα121,122. 
We found a similar, yet stronger phenotype in CCl4-induced acute 
hepatocyte injury. Intraperitoneal CCl4, which is metabolized in a similar CYP2E1-
dependent manner as ethanol, induces an early ER stress response. In this 
model of liver injury, when analyzed livers of WT mice at various time points after 
a single administration of CCl4, we found an early increase in sXbp1 mRNA 
splicing one and two hours after administration of CCl4 (Fig. 2.10C). Analysis of 
cell populations from murine livers showed that CCl4 selectively upregulated 
Xbp1 mRNA splicing in hepatocytes but not in LMNCs (Fig. 2.10D) 
Previous reports have shown that ER stress results in IRF3 activation in mouse 
embryonic fibroblast, and that Xbp1 splicing enhances the IFN-β response in 
immune cells123,124. To test if direct induction of ER stress can lead to IRF3 
phosphorylation, we treated WT primary hepatocytes with thapsigargin in vitro 
and found an early increase in phosphorylated IRF3 (Fig. 2.10E). Inhibition of 
Tank-binding kinase 1 (TBK1), a kinase responsible for IRF3 phosphorylation, 
with BX795 showed a dose-dependent reduction in IRF3 phosphorylation in 
thapsigargin-treated hepatocytes (Fig. 2.10E). This finding indicated that 
activation of IRF3 in hepatocytes by ER stress is dependent on STING and 
TBK1. Next, we observed that thapsigargin failed to induce IRF3 phosphorylation 
in hepatocytes isolated from the Tmem173gt mice (Fig. 2.10F), which lack the 
STING protein.   
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Figure 2.10 ER stress activates IRF3 via TBK1 and STING in early ALD  
WT mice received a single dose of ethanol. At indicated time-points, presence of 
ER stress was measured by evaluation of spliced Xbp1 (sXbp1) mRNA in liver 
lysate (A) or isolated hepatocytes and liver mononuclear cells (LMNCs) (B) via 
PCR on agarose gel. WT mice received a single dose of i.p. injection of CCl4. At 
indicated time-points, presence of ER stress was measured by evaluation of 
spliced Xbp1 (sXbp1) mRNA in liver lysate (C) or isolated hepatocytes and liver 
mononuclear cells (LMNCs) (D) via PCR on agarose gel. N=3 mice per time-
point. WT primary hepatocytes were pre-treated with DMSO or BX795 (10 µM 
and 100 µM), and stimulated with thapsigargin (1μM). Whole-cell lysate was 
analyzed for p-IRF3 by western blot (E). Primary hepatocytes from WT and 
Tmem173gt mice were stimulated with thapsigargin (1μM) and analyzed for p-
IRF3 and for GRP78 (F). * P < 0.05 vs baseline.  
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ER stress as a therapeutic target in ALD  
To investigate the role of endoplasmic reticulum (ER) stress on liver 
inflammation and hepatocyte death, we will administer animals with ER stress 
inhibitors (ERSI) orally before and/or during acute/chronic ethanol administration. 
Alcohol consumption causes ER stress in the liver. ER stress is accompanied by 
the unfolded protein response, which serves to maintain homeostasis in the cell 
to aid in recovery119. High levels or sustained ER stress is associated with cell 
death115,125,126. More recently, ER stress has been directly, linked with activation 
of STING in the ER, resulting in phosphorylation of IRF333,124, a critical innate 
immune transcription factor that can trigger apoptosis in hepatocytes through 
association with pro-apoptotic BAX110,127. 
We hypothesize that pharmacological inhibition of ER stress via administration of 
a small molecule protein-folding chaperons, such as 4-phenylbutyrate (4PBA), 
will protect cell from STING and IRF3-mediated apoptotic signaling. The use of 
this and other inhibitors, like tauroursodeoxycholic acid (TUDCA) 128 has been 
shown to be beneficial in a model of Type 2 diabetes 129 and in a model of 
NASH130. 4PBA has been shown to be effective by administration via gavage or 
in the drinking water, as well as through intraperitoneal injection. Here, we tested 
in a pilot experiment if oral administration of the drug was equally as effective as 
self-administration by the mice. For this, we mixed 4PBA directly in the liquid diet 
and found comparable decrease in spliced Xbp1 protein in the liver as mice that 
received a daily gavage of 4PBA (data not shown). For subsequent experiments, 
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WT mice were fed Lieber-DeCarli liquid diet (PF or ethanol) containing 4PBA at a 
dose of 2 mg/kg daily as part of an acute-on-chronic ethanol diet. This model of 
ethanol-induced liver injury was chosen because we had established that IRF3 
was involved in early late chronic liver injury from ethanol, whereas STING 
played a major role after acute-only or acute-on-chronic liver injury, but not at the 
culmination of a four-week ethanol feeding. Therefore, within this model, we 
could carefully control for time-sensitive dynamics of IRF3 phosphorylation, 
which peaked at 4hrs, while still testing for both, acute and chronic events, 
through the administration of a single binge as part of or independently from a 
ten-day ethanol administration model. We found that administration of 4PBA as a 
preventative measure, effectively reduced ethanol-induced liver injury (Fig. 
2.11A). Importantly, 4PBA was effective at reducing phosphorylation of IRF3 4 
and 9 hours post ethanol binge in liver lysate (Fig. 2.11B). As a positive control, 
we found that daily dose of 4PBA at 2 mg/kg was effective in reducing 
tunicamycin-induced ER stress in the liver (data not shown). Interestingly, we 
found elevated levels of phosphorylated IRF3 in liver lysate 12 hours after 
tunicamycin intraperitoneal injection (Fig. 2.11B) when injected at 2 mg/kg131.  
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Figure 2.11 Therapeutic inhibition of ER stress attenuates liver injury and 
IRF3 phosphorylation 
WT mice were fed a 10-day acute-on-chronic Lieber-DeCarli ethanol diet 
containing 4PBA (2 mg/kg/day). Mice were sacrificed 4 and 9 hours after an 
ethanol binge. Liver injury was assessed by serum ALT (A). Phosphorylation of 
IRF3 from whole-cell liver lysate of mice treated with or without 4-PBA(B). Mice 
injected with tunicamycin (TM) were used as positive control of ER stress.   
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Building upon previous findings, our data indicate that acute administration 
of ethanol or CCl4 results in hepatocyte-specific ER stress and phosphorylation of 
IRF3 in vivo, and that in vitro inhibition of a kinase upstream of IRF3 inhibited 
phosphorylation of IRF3 induced by ER stress. Our data support the hypothesis 
that liver injury activates STING and IRF3 in hepatocytes via ER stress, as 
summarized in Figure 2.12. 
Collectively, our data demonstrated that activation of IRF3 in ALD is 
triggered by the ER stress in hepatocytes via the adaptor STING. As such, ER 
stress is a potential therapeutic target in ALD. Thus, STING and IRF3 are key 
determinants of ALD, linking ER stress signaling with the mitochondrial pathway 
of hepatocyte apoptosis. 
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Figure 2.12 Schematic for STING and IRF3 activation by ER stress 
Hepatocellular injury, from ethanol or CCl4, induces ER stress and STING 
activation in the ER. This leads to recruitment of TBK1, which phosphorylates 
and activates IRF3. This signaling sequence results in IRF3 associating with BAX 
on the mitochondrial membrane, and an activation of apoptosis through 
Caspase-8 and Caspase-3.  
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The role of cGAS 
There are several intracellular double-stranded (ds) DNA sensors that 
activate STING signaling in response to viral infection. The cyclic dinucleotide 
2’3’-cGAMP, synthesized by the dsDNA cytosolic sensor cGAMP synthase 
(cGAS), activates STING. We hypothesized that cGAS may be an upstream 
activator of STING and IRF3 in ALD. We found complete protection from liver 
injury and inflammation in IRF3-KO mice. However, only partial attenuation of 
liver injury was observed in STING-deficient mice. The strongest protection was 
observed early during the course of a chronic ethanol feeding or from acute 
ethanol binge. For this reason, we decided to test the role cGAS using the ten-
day NIAAA model of acute-on-chronic ethanol injury 92 with slight modifications 
(Fig. 1.7A). We would incorporate a group of mice that did not receive a binge 
after 10 days of Lieber-DeCarli ethanol diet, allowing us to test the effects of 
acute injury separately from the chronic. In addition, some mice were sacrificed 4 
hours post ethanol binge, rather than the 9 hours, as is recommended by the 
NIAAA model. These two time-points would allow us to observe peak IRF3 
phosphorylation, which occurs in the first few hours post binge, while the 9-hour 
time point would allow us to observe overall effects associated with peak liver 
injury. We found that cGAS-KO mice had decreased levels of serum ALT, 
improved liver morphology and decreased F4/80 mRNA after acute binge at 4 
and 9 hours (Fig. 2.13A-C). Interestingly, cGAS-KO mice that received only 
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chronic Lieber-DeCarli ethanol diet for 10 days (without a binge) had comparable 
liver injury as WT mice.   
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Figure 2.13 cGAS deficiency protects from acute-on-chronic liver injury  
WT and cGAS-KO mice were fed an ethanol Lieber-DeCarli diet for 10 days with 
a single ethanol binge on day 10. Some mice were sacrificed 4 or 9 hours post 
ethanol binge. Pair-fed mice received a binge of iso-caloric maltodextrin. Liver 
injury was assessed by serum ALT (A) and H&E liver histology (200X 
magnification) (B). Livers were analyzed for F4/80 mRNA expression (C). n=5-7 
mice per time-point. * P < 0.05 vs baseline.  
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Given that cGAS-KO mice were not protected from 10 days of chronic 
ethanol, but had strong protection from the acute effects of acute-on-chronic 
ethanol, we then tested if cGAS-KO were protected from liver injury in the acute 
ethanol binge model of early ALD. We found lower levels of serum ALT after an 
ethanol binge in cGAS-KO mice compared to their WT controls (Fig. 2.14A). We 
then tested if cGAS signaling was a determinant for ethanol-induced IRF3 
phosphorylation in the liver. We found no detectable increase in phosphorylated 
IRF3 in liver from cGAS mice compared to WT mice (Fig. 2.14B). Lastly, we 
tested if cGAS mediated the apoptotic role associated with IRF3 activation. We 
found no increase in Caspase-3 cleavage in livers from cGAS-KO mice after a 
single ethanol binge compared to WT mice. Together, this data suggested that 
IRF3 phosphorylation and concomitant pro-apoptotic signaling is mediated by 
cGAS in early ALD. This phenotype was present from a single stand-alone binge 
or as part of an acute-on-chronic ethanol injury.   
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Figure 2.14 cGAS mediates acute ethanol-induced IRF3 phosphorylation 
WT and cGAS-KO mice were given a single ethanol dose. Liver injury was 
assessed by serum ALT (A). Livers were analyzed at indicated time-points and 
tested for phosphorylated IRF3 (p-IRF3) (B) and cleaved Caspase-3 (C) protein 
by western blot (B). Densitometry was measured by ImageJ. * P < 0.05 vs 
baseline. 
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Mitochondrial DNA release as inception of disease 
cGAS is an intracellular dsDNA sensor. cGAS is important in creating an 
anti-viral state in the presence of replicating viruses in the cytoplasm, leading to 
IFN-β through IRF3 activation. However, dsDNA from many sources, including 
host DNA, can activate cGAS, as it is not sequence dependent. We hypothesized 
that ethanol-induced mitochondrial damage, and subsequent mitochondrial DNA 
(mtDNA) release, may be responsible for activating cGAS. To test this, we 
isolated plasma from mice 2 and 4 hours post an ethanol binge. We measured 
for COX1 as a marker for mtDNA using digital droplet PCR (ddPCR). This 
approach allowed us to have highly sensitive detection method. Moreover, 
ddPCR yields absolute quantities of probe in our sample, rather than relative 
values compared to a reference gene, which is useful since plasma DNA is not 
expected to have unaltered nucleotide levels. We detected an increase in 
circulating mtDNA at 2 and 4 hours (Fig. 2.15A). To test if mtDNA was directly 
responsible for IRF3 phosphorylation, we had to make use of an in vitro system 
to manipulate endogenous levels of mtDNA. We used Huh7 cells, a transformed 
human hepatoma cell line. We incubated cells with ethidium bromide (0.2 µg/ml) 
and supplemented with 50 µg/ml uridine and 1 mM sodium pyruvate for 40 days 
to deplete mtDNA132. We confirmed mtDNA depletion by Cytochrome C Oxidase 
I (COX1) and NADH Dehydrogenase Subunit 6 (ND6) mRNA (Fig 2.15B). We 
evaluated by microscopy whether ethidium bromide treatment reduced the 
number of overall mitochondria per cell. We found a comparable number of 
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mitochondria in WT and mtDNA-depleted Huh7 cells (Fig 2.15C), consistent with 
previous reports133,134. Together, this suggested that prolonged ethidium bromide 
incubation led to reduction of mtDNA, but not in overall number of mitochondria. 
We then tested if in vitro ethanol stimulation resulted in differences in 
phosphorylated IRF3 in these two cells. Stimulation with transfected dsDNA with 
poly(dA:dT)/LyoVec was used a positive control for cGAS-mediated IRF3 
activation. We found an increase in ethanol-induced phosphorylated IRF3 in WT 
Huh7 cells. There was no detectable increase in phospho-IRF3 or cleaved 
Caspase-3 in the mtDNA-depleted cells (Fig 2.15D). This suggested that 
ethanol-induced cGAS-mediated activation of IRF3 and associated apoptotic 
signaling relied on mtDNA release into the cytoplasm. We hypothesize that 
apoptotic or necrotic cells from ethanol toxicity likely released their contents, 
including mtDNA, into circulation, a signal that was stronger at 4 hours than at 2 
hours.  
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Figure 2.15 Ethanol-induced mitochondrial DNA determines IRF3 
phosphorylation 
WT mice were given a single ethanol dose. Plasma was isolated and evaluated 
for circulating mitochondrial DNA (mtDNA) by measuring COX1 mRNA by 
ddPCR (A). Huh7 cells were incubated with ethidium bromide (0.2 µg/ml), 
supplemented with 50 µg/ml uridine and 1 mM sodium pyruvate for 40 days to 
deplete mtDNA. mtDNA was confirmed by COX1 and ND6 mRNA by RT-PCR 
(B). 18s was used as non-mitochondrial mRNA control (C). WT and mtDNA-
depleted Huh7 cells were evaluated for total mitochondria by confocal 
microscopy with MitoTracker staining (yellow), counterstained with DAPI (blue) 
(C). WT Huh7 and mtDNA-depleted Huh7 cells were stimulated with ethanol or 
transfected dsDNA (poly (dA:dT)/Lyovec), and evaluated for phospho-IRF3 and 
cleaved Caspase-3 by western blot (D).   
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Accumulation of oxidized DNA in patients with Alcoholic Hepatitis 
We hypothesized if ethanol consumption resulted in damaged 
mitochondria, perhaps this damage could accumulate in the liver. If so, it is likely 
to be present in the form of oxidized DNA. It has been reported that ethanol 
causes DNA damage and ROS-mediated oxidative stress135-137. We therefore 
probed livers from patients with acute alcoholic hepatitis (AH) for 8-Hydroxy-2-
deoxy-guanosine (8-OHdG), a marker for oxidative DNA damage138. Compared 
to Normal controls, livers from disease patients with AH had increased 8-OHdG 
staining (Fig. 2.16A). The staining appeared to be cytoplasmic, or perhaps in 
mitochondria. To test this, we performed dual-immunofluorescent staining of a 
mitochondrial marker (COXIV) and 8-OHdG. Interestingly, the majority of the 8-
OHdG staining was not localized near mitochondria (Fig. 2.16B,C). There was a 
quantifiable increase in 8-OHdG staining in diseased livers. We hypothesize that 
8-OHdG staining may be the result of dead mitochondria or cytoplasmic mtDNA 
released into the cytoplasm.   
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Fig. 2.16 Oxidized DNA increases in patients with alcoholic hepatitis 
Human livers from patients with acute alcoholic hepatitis and healthy normal 
controls were stained for 8-OHdG as a marker of oxidized DNA damage (A). 
Dual immunofluorescence staining for COXIV (green), 8-OHdG (red), and DAPI 
(blue) in livers from patients with alcoholic hepatitis and healthy controls (B). A 
binary mask was created in ImageJ to quantify of 8-OHdG staining (C). Shown 
are livers from two representative patients per condition.  
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Propagation of IRF3 activation through gap junctions 
IRF3 phosphorylation of naïve cells in vitro 
Inhibition of gap-junction communication limited the extent of the injury 
and protected against liver failure in vivo. Interestingly, in response to viral 
infection, cyclic dinucleotides were shown to spread through gap junctions50. 
Cyclic dinucleotide communication through gap junctions triggers STING and 
IRF3 activation in neighboring cells, thus amplifying the anti-microbial response. 
Gap junction communication through Cx32, the predominant connexin expressed 
by hepatocytes, can be blocked in vitro and in vivo using small-molecule inhibitor 
2-aminoethoxydiphenyl borate (2APB), resulting in interference of intercellular 
Ca2+ ion flux139,140. We hypothesize that cyclic dinucleotides are small enough to 
be able to similarly cross hepatic hemi-channels and be blocked by 2-APB. We 
first tested this hypothesis with an in vitro assay for gap junction communication.  
In a parachute assay 141,142, functional gap junctions form between plated 
cells and a new donor cell, the ‘parachute’ cell, which is introduced to the culture. 
This occurs in vitro within two hours of plating parachute cells and can be 
visualized via real-time confocal microscopy in primary hepatocytes as calcein-
AM, a gap junction-permeable dye, is diffused and transferred from parachute 
cells to naïve neighboring cells (Fig. 2.17A). Gap junction-mediated cytoplasmic 
transfer can be blocked in vitro with pre-treatment of 2APB for 15 minutes. (Fig. 
2.17B). In a separate parachute assay, WT primary hepatocytes pre-incubated 
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with EtOH in vitro had phosphorylated IRF3 (Fig. 2.17C,D in orange). 
Additionally, these donor cells were able to induce phosphorylation of IRF3 when 
plated on top of a monolayer of naïve cells (Fig. 2.17 C,D one recipient cell 
highlighted in white). This shows that propagation of ethanol-induced IRF3 
signaling can be propagated via gap junctions in vitro.  
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Figure 2.17 Gap junctions propagate EtOH-induced IRF3 activation in vitro 
WT primary hepatocytes were plated (naïve); other (donor) cells were loaded 
with gap junction-permeable dye (calcein-AM, green). Cytoplasmic exchange 
was observed via confocal microscopy (A). Under same conditions, cells were 
pre-incubated with gap junction inhibitor 2APB for 15 min (B). In a separate 
experiment, WT primary hepatocytes were incubated in 200 mM EtOH for 2hours 
(donor; highlighted with orange circle) and plated on hepatocyte monolayer 
(naïve; highlighted with white circle). Only naïve cells were labeled with DAPI 
(blue). All cells were fixed, stained for Actin (green) and p-IRF3 (red) and imaged 
(C). Same experiment as C, with images stacked on z-axis to create 3D image, 
rotated forward 45 degrees (D). White bar = 10 µm. 
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Gap junctions as therapeutic target in ALD 
Given the zonal distribution of hepatocyte damage in ALD, we hypothesize 
that activation of IRF3 via gap junction-mediated cyclic dinucleotide contributes 
to the gradient of hepatocyte damage and subsequent amplification of cell death 
and inflammation in ALD. This hypothesis was supported in a previous report on 
drug-induced liver failure, where inhibition of Cx32 via 2APB was effective in 
preventing liver injury, inflammation and lethality from a lethal dose of APAP in 
mice49. Based on our observations that showed propagation of ethanol-induced 
signals through gap junctions resulting in IRF3 phosphorylation in vitro, 
presumably cyclic dinucleotides, we hypothesized if hepatic gap junctions could 
be a therapeutic target in ALD. To test this, we administered a 10-day Lieber-
DeCarli acute-on-chronic ethanol diet to WT mice, following a similar rationale as 
that used within the 4PBA and the cGAS experimental model. More specifically, 
this model would allow us to directly and comparably test if cGAS played a role in 
ALD pathogenesis in acute, chronic or acute-on-chronic ALD pathogenesis, while 
allowing us to tightly control time-specific dynamics, such as IRF3 
phosphorylation. Detection of IRF3 phosphorylation would serve as clear 
indication of whether cGAS-deficient mice played a role or not in activating IRF3, 
and therefore served as a critical internal positive control in the WT control group. 
Some mice received daily intraperitoneal injections of 2APB. Mice that received 
2APB had protection from liver injury and histological liver features (Fig. 
2.18A,B). We then tested if the improved liver phenotype from 2APB was a result 
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of dampened IRF3 signaling. We found no detectable IRF3 phosphorylation in 
these mice at any of the time-points tested, with or without binge (Fig. 2.18C). 
We were surprised at how effective 2APB was at preventing ALD, since some 
hepatocytes would still be expected to metabolize ethanol in be exposed to 
hepatotoxic effects. We hypothesize that dampening the amplification of IRF3 
activation and reduced inflammation allowed for the liver to maintain homeostasis 
in a manageable manner, even during ongoing acute and chronic ethanol 
exposure (Fig. 2.19).    
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Figure 2.18 Therapeutic inhibition of hepatic gap junction communication 
attenuates liver injury and IRF3 phosphorylation 
WT mice were fed a 10-day acute-on-chronic Lieber-DeCarli ethanol diet 
containing 2APB (20 mg/kg/day). Some mice were sacrificed 4 and 9 hours after 
an ethanol binge. Liver injury was assessed by serum ALT (A) and H&E liver 
histology (B). Phosphorylation of IRF3 from whole-cell liver lysate of mice treated 
with or without 2APB (C).   
 117 
  
10-day EtOH
hr: PF
pIRF3
IRF3
No Binge 4hr Binge 9hr Binge
+2APB, i.p.
WT 2APB
PF
N
o 
B
in
ge
4h
r 
B
in
ge
9h
r 
B
in
ge
A B
C
PF 0hr 4hr 9hr
0
10
0
20
0
30
0
se
ru
m
 A
LT
  (
U
/L
)
2APB
WT
+ 1x EtOH binge
*
**
10 days EtOH
**
*
 118 
Figure 2.19 Schematic of gap junction-mediated propagation of STING 
activation  
Upon activation from mtDNA, cGAS secretes cyclic dinucleotide cGAMP, which 
binds and activates STING. cGAMP mean also travels via Cx32 gap junctions, 
spreading activation of STING and IRF3 to adjacent cells.   
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CHAPTER THREE: INFLAMMASOME SIGNALING 
IL-1β maturation is a two-step process. LPS induces the pro-IL-1β gene 
expression but an additional, inflammasome-mediated signal is required for 
cleavage of pro-IL-1β protein to mature IL-1β that is released from inflammatory 
cells143. We sought to identify the inflammasome sensor and the components 
released from damaged hepatocytes that serve as a second signal for IL-1β 
release using in vivo and in vitro models. 
NLRP3 as the inflammasome sensor in ALD 
NLRP3-deficient mice protected from inflammasome activation in ALD 
Our data indicated that uric acid and ATP released from damaged 
hepatocytes are required for activation of liver immune cells. The mechanism by 
which uric acid and ATP activate inflammation requires the NLRP3 
inflammasome143. Using the NLRP3, immune cells recognize endogenous 
“danger” signals, including ATP, uric acid and crystalline substances, and trigger 
activation of Caspase-1 and maturation of IL-1β71. Therefore, we evaluated mice 
lacking NLRP3, and asked whether NLRP3 provides a mechanistic link between 
hepatocyte-derived danger signals, inflammasome activation and liver 
inflammation in ALD.  
Deficiency of NLRP3 prevented ethanol-induced activation of the 
inflammasome in the liver, as indicated by the diminished levels of cleaved p10 
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fragment of Caspase-1 (Fig. 3.1A) and cleaved IL-1β in the liver and in the 
serum (Fig. 3.1B,C), compared to WT mice. Active secreted IL-1β upregulates 
inflammatory cytokines, including TNF-α, promotes steatosis and sensitizes 
hepatocyte to cytotoxicity induced by TNF-α64,144-146. Accordingly, lack of 
activation of inflammasome and IL-1β in NLRP3-deficient mice was accompanied 
by protection from liver inflammation, steatosis and damage, as indicated by the 
absence of ethanol-induced upregulation of TNF-α and IL-1β in the liver and in 
the serum (Fig. 3.1C),  as well as improved findings on H&E and amelioration of 
ALT increase in the serum (Fig. 3.1D). The extent of protection from liver 
inflammation and injury in NLRP3-KO mice was comparable to that previously 
observed in mice deficient in Caspase-1/11. Since Caspase-1 is the effector 
molecule of inflammasomes71, our data suggested that NLRP3 is a major 
activator of the inflammasome in ALD. At the time of these experiments, there 
was no commercially available mouse deficient in Caspase-1 only. It should be 
noted that although there have been reports of Caspase-11 involvement in the 
French-Tsukamoto model of ALD pathogenesis, I was unable to detect cleavage 
of Caspase-11 in any of the ALD models I have experimented with, such as 
single binge,  4-week chronic or in the 10-day plus binge model of ALD. Although 
an absence of Caspase-11 cleavage detection in my hands doesn’t rule out its 
potential role, this was sufficient evidence for me to assess that its role, at best, 
is at not greater than that of Caspase-1 in these models I tested.  
 122 
Figure 3.1 Deficiency of NLRP3 ameliorates ethanol-induced liver 
inflammation  
WT or NLRP3-KO mice were fed control (Pair-fed) or ethanol diet. After 4 weeks, 
we evaluated cleavage of Caspase-1 (A) and cleavage of IL-1β (B) by western 
blot. Levels of total IL-1β and TNF-α in circulation and liver lysate were assessed 
by ELISA (C). Liver damage was assessed by liver H&E histology and serum 
ALT (D). n = 7-15 mice per group. * < 0.05 versus baseline. Original 
magnification, 200x.  
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Endogenous sterile danger signals, ATP and uric acid, are increased in ALD 
Given the effect of ethanol on mitochondrial function and metabolism of 
purine nucleotides, we studied the role of ATP and uric acid, two well-
characterized activators of the inflammasome147. First, we asked whether alcohol 
modulates the levels of uric acid and ATP. We evaluated uric acid and ATP in the 
serum and liver of WT mice after 4 weeks of Lieber-DeCarli ethanol or control 
diet feeding. We hypothesized that, if these DAMPs were to be accurately 
measured in circulation in mice, they were most likely to be detected in vivo 
during peak levels of inflammation, i.e. after four-week ethanol diet, since at the 
time, the NIAAA model had not been thoroughly tested. We observed that liver 
damage caused by ethanol was accompanied by statistically significant 
increases in ATP and uric acid (Fig. 3.2A) levels in the serum and in the liver 
(Fig. 3.2B). This data indicated that liver damaged by ethanol releases metabolic 
danger signals, uric acid and ATP.   
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Figure 3.2 Endogenous inflammasome activators, ATP and uric acid, are 
increased in ALD 
Wild-type mice were fed control (pair-fed) or alcohol Lieber-DeCarli diet. After 4 
weeks, liver damage and uric acid and ATP in serum (A) and liver were 
evaluated (B). N= 15 (ethanol-fed); 5 (pair-fed). *P < 0.05 vs. baseline.  
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Hepatocyte-derived DAMPs as activators of NLRP3  
To evaluate the source of increased ATP and uric acid in ALD, we 
exposed primary murine hepatocytes to ethanol or heat-shock (HS), and 
observed early release of ATP and uric acid into hepatocyte supernatants along 
with the development of hepatocyte injury (Fig. 3.3A,B). In contrast, ATP or uric 
acid was not detected in supernatants from liver mononuclear cells (LMNCs) 
exposed to ethanol or HS (Fig. 3.3C), indicating that increased ATP and uric acid 
detected in serum and livers of alcohol-fed mice was most likely derived from 
hepatocytes and not mononuclear cells. Treatment of LPS-primed LMNCs with 
uric acid crystals or ATP significantly increased the release of IL-1β protein 
indicative of inflammasome activation, and a similar increase in IL-1β was 
observed when LMNCs were treated with soluble uric acid (Fig. 3.3D). This data 
supported the notion that ATP and uric acid are released from damaged 
hepatocytes and are subsequently recognized as pro-inflammatory signals by 
LMNCs. This data indicated that ethanol-exposed hepatocytes release significant 
amounts of uric acid and ATP, and this observation was consistent with previous 
reports that uric acid and ATP are present in high concentrations in 
hepatocytes148,149.  
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Figure 3.3 Damaged hepatocytes, but not liver mononuclear cells, release 
endogenous metabolic activators of the inflammasome, ATP and uric acid 
Primary murine hepatocytes were treated with 800 mM ethanol, and levels of 
LDH, indicating hepatocyte death, ATP and uric acid were evaluated in 
supernatants at indicated time points (A). Primary murine hepatocytes were 
cultured at 45°C (heat-shock) or 37°C (control) and levels of LDH, ATP and uric 
acid were evaluated in supernatants at indicated time points (B). Murine liver 
mononuclear cells (LMNCs) were treated with 800 mM ethanol, and levels of 
LDH, indicating cell death, ATP and uric acid were evaluated in supernatants at 
indicated time points (C). Murine LMNCs were cultured at 45°C (heat-shock) or 
37°C (control) and levels of LDH, ATP and uric acid were evaluated in 
supernatants at indicated time points (C). LMNCs isolated from wild-type mice 
were pretreated with indicated doses of LPS. In some groups, ATP (5 mM) was 
added after 2 hours of LPS stimulation and supernatant was collected 1 hour 
afterward. In other groups, soluble uric acid (100 μg/mL) or monosodium urate 
crystals (MSU, 250 μg/mL) were added after 2 hours of LPS stimulation and 
supernatant was collected at 24 hours (D). Stimulations were performed in 
triplicates. *P < 0.05 vs. baseline.  
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Uric acid and ATP as second signal 
Inhibition of ATP signaling in vivo 
Our data indicating that exposure to ethanol increased circulating and liver 
ATP levels prompted us to ask whether ATP was required for activation of 
inflammasome and inflammation in chronic ALD. We used mice deficient in the 
P2rx7 receptor (purinergic receptor P2x, ligand-gated ion channel 7), which is 
activated by extracellular ATP71,150. We observed that P2rx7-deficient mice were 
protected from alcohol-induced liver damage as indicated by improved liver 
histology on H&E staining and significantly lower serum ALT levels compared to 
wild-type mice (Fig. 3.4A,B). Ethanol-induced increase in the inflammatory 
cytokine, TNF-α (Fig. 3.4C), was prevented in the serum and liver of mice 
deficient in ATP signaling compared to WT mice. In contrast to WT mice, there 
was no ethanol-induced increase in serum IL-1β in P2rx7-deficient mice (Fig. 
3.4D). IL-1β in the serum is present predominantly in the bioactive form, 
suggesting a lack of inflammasome activation in the absence of ATP signaling. 
Indeed, the deficiency of P2rx7 prevented alcohol-induced activation of the 
inflammasome in the liver, demonstrated by undetectable levels of p10, the 
cleavage product of the inflammasome effector molecule, Caspase-1 (Fig. 3.4E). 
This data supported the hypothesis that ATP plays an important role in activation 
of the inflammasome as well as in development of liver inflammation, steatosis 
and injury in ALD. 
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Figure 3.4 ATP signaling is required for inflammasome activation and liver 
inflammation in ALD 
WT or P2rx7-KO mice were fed control (pair-fed) or Lieber-DeCarli alcohol diet. 
After 4 weeks, liver damage was assessed by liver H&E histology (A) and serum 
ALT (B). We evaluated levels of TNF-α in the serum and in the liver (C) and IL-1β 
in the serum by ELISA (D). We evaluated cleavage of Casp-1 in the liver by 
western blot (E). N= 7-15 (ethanol-fed, per genotype); 5 (pair-fed, per genotype). 
Numbers in the graphs indicate P values. *P < 0.05 vs. baseline. Original 
magnification, 200x.  
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Targeting uric acid in vivo 
Our data indicated that exposure to ethanol increases the release of uric 
acid from the damaged liver. To evaluate whether uric acid is required for liver 
inflammation in ALD, we used two previously described strains of transgenic (Tg) 
mice overexpressing uricase (urate oxidase, UOX), an enzyme that degrades 
uric acid151,152. In the first strain, referred to as secreted uricase (ssUOX)-Tg, 
uricase is secreted into the extracellular fluids, depleting uric acid from the 
interstitial fluids, tissues and serum151. In the second strain, referred to as 
intracellular uricase (intUOX)-Tg, uricase is targeted to peroxisomes and reduces 
intracellular pools of uric acid. After intUOX-Tg cells die and uricase is released, 
the enzyme also depletes uric acid from the environment of dead cells151. Both 
strains of Tg mice showed absence of alcohol-induced increase of uric acid in the 
serum and in the liver (Fig. 3.5A), compared to WT mice. The intUOX-Tg 
demonstrated a trend towards lower baseline levels of uric acid in the serum and 
in the liver compared to ssUOX-Tg mice, but the difference was not significant 
(Fig. 3.5A). 
We observed that depletion of uric acid in ssUOX-Tg or intUOX-Tg mice 
provided significant protection from liver damaged as evaluated by H&E liver 
histology and serum ALT (Fig. 3.5B,C). Importantly, uric acid-deficient mice 
showed lack of alcohol-induced increase of IL-1β in the serum (Fig. 3.5D), which 
indicated decreased inflammasome activation in absence of uric acid signaling. 
Indeed, further analyses showed that depletion of uric acid in ssUOX-Tg or 
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intUOX-Tg mice prevented alcohol-induced activation of inflammasome in the 
liver, demonstrated by absent cleavage of the inflammasome effector molecule, 
Caspase-1, with more pronounced repression of Caspase-1 cleavage in intUOX-
Tg, compared to ssUOX-Tg mice (Fig. 3.5E). This data supported our hypothesis 
that uric acid is involved in activation of inflammasome and development of liver 
inflammation, steatosis and injury in ALD.  
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Figure 3.5 Uric acid is required for inflammasome activation and liver 
inflammation in ALD 
WT, ssUOX-Tg or intUOX-Tg mice were fed control (pair-fed) or alcohol Lieber-
DeCarli diet. After 4 weeks, we evaluated levels of uric acid in serum and in the 
liver (A). Liver damage was assessed by liver H&E histology (B) and serum ALT 
(C). Levels of IL-1β in were evaluated in the serum (D). We evaluated cleavage 
of Caspase-1 in the liver (E). N= 6-9 (ethanol-fed, per genotype); 4-5 (pair-fed, 
per genotype). Numbers in the graphs indicate P values. *P < 0.05 vs. baseline. 
Original magnification, 200x.  
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Therapeutic intervention with allopurinol or probenecid 
Finally, we asked whether uric acid and ATP could represent potential 
therapeutic targets in alcoholic steatohepatitis. To deplete uric acid, we evaluated 
two anti-gout medications used in humans: allopurinol, an inhibitor of xanthine 
oxidase, an enzyme that synthesizes uric acid, and probenecid, a compound 
promoting renal excretion of uric acid.  
 Treatment with allopurinol significantly attenuated alcohol-induced 
histological changes in the liver on H&E staining and reduced serum ALT (Fig. 
3.6A,B). This protection from alcohol-induced liver injury was consistent with 
significant, albeit incomplete, reduction in alcohol-induced cleavage of Caspase-
1 (Fig. 3.6C), whereas full prevention of Capase-1 cleavage in the liver was 
observed when mice were treated with probenecid (Fig. 3.6C). Allopurinol-
treated mice also demonstrated complete protection from TNF-α increase in the 
serum and in the liver (Fig. 3.6D). Amelioration of alcohol-induced damage on 
histology was consistent with a previous report153. Importantly, daily intragastric 
administration of allopurinol or probenecid significantly reduced levels of uric acid 
in the serum of alcohol-fed mice, and treatment with allopurinol decreased 
baseline levels of serum uric acid to almost non-detectable levels (Fig. 3.6E). 
However, treatment with probenecid provided superior protection from ALD. This 
additional protective effect implied that mechanisms beyond promotion of uric 
acid excretion may be responsible for the protective effect of probenecid. It has 
been reported that probenecid inhibits pannexin-1 channels154, which play an 
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essential role in ATP signaling155. Thus, the superior protective role of 
probenecid in ALD was likely explained through the promotion of uric acid 
excretion as well as inhibition of ATP signaling, indicating a synergistic effect of 
uric acid and ATP on inflammasome activation in ALD.  
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Figure 3.6 Pharmacologic depletion of uric acid and inhibition of ATP 
signaling prevents alcoholic steatohepatitis and fibrosis 
 WT mice treated with daily intragastric doses of vehicle (PBS), allopurinol or 
probenecid (100 mg/kg body weight) were fed control (pair-fed) or alcohol Lieber-
DeCarli diet. After 4 weeks, liver damage was assessed by H&E histology (A) 
and serum ALT (B). We evaluated liver cleavage of Caspase-1 by western blot 
(C) and levels of liver TNF-α in the serum by ELISA (D). We evaluated the levels 
of uric acid in the serum (E). N= 9-10 mice (ethanol-fed, per treatment); 3-5 mice 
(pair-fed, per treatment). Numbers in the graphs indicate P values. *P < 0.05 vs. 
baseline. Original magnification, 200x.  
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Overall, this data suggested the presence of cross-talk between alcohol-
damaged hepatocytes and liver immune cells and demonstrated that 
inflammatory activation of LMNCs is augmented by hepatocyte-derived uric acid 
and ATP. This signaling axis is dependent on a feed-forward induction via 
inflammasome activation and release of IL-1β, reflecting the dependency of IL-1β 
induction on autocrine loop mediated by IL-1 receptor145,156,157.  
Recovery with Anakinra 
Impaired liver regeneration correlates with poor survival in patients with 
severe acute alcoholic hepatitis (AH).158 The inability of patients with AH to 
restore fully functional hepatocyte mass and function has been reported in 
multiple clinical studies, 158,159 but the mechanisms of this phenomenon are yet to 
be elucidated. Studies using mouse models of ALD have focused predominantly 
on the pathogenesis of ALD (reviewed in ref.160,161) but have not addressed 
hepatocyte regeneration during the recovery phase. The aim of this study was to 
propose a mouse model that would provide a tool to study liver recovery after 
exposure to chronic ethanol.  We also used this model to investigate whether 
liver recovery can be facilitated by inhibition of IL-1, a cytokine crucially involved 
in the pathogenesis of ALD through NLRP3 activation of the inflammasome in 
mice64,162,163. 
In our model, we attempted to mimic human drinking patterns of acute-on-
chronic ethanol exposure in alcoholic patients. WT mice were fed the Lieber-
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DeCarli ethanol diet for 4 weeks. To enhance liver injury, mice received 3 acute 
doses of ethanol via an intragastric probe during the last 3 days of ethanol 
feeding (Maximal Injury) (Fig. 1.7). Subsequently, all mice were transitioned to 
the control diet with no ethanol and randomly assigned to daily treatment with 
Anakinra (IL-1Ra, an inhibitor of IL-1 signaling) or saline (Recovery phase), both 
delivered via intraperitoneal injections. Mice were sacrificed at baseline, at the 
point of maximum injury, and during the recovery phase, 1, 2, 3, 4 and 7 days 
after transition to control diet.  
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Figure 3.7 Design of murine model of alcoholic hepatitis 
WT mice were treated with ethanol diet for 4 week and received three intragastric 
gavages of EtOH (5 g/kg) during the last 3 d of ethanol feeding (“Max. Injury,” 
red). After day 28, all mice were switched to control diet, and daily treatment with 
Anakinra or saline was initiated (Recovery Phase, blue). Baseline (green) refers 
to mice sustained on iso-caloric control liquid diet for the duration of the feeding 
(week 5, day 7).  
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Hepatocyte Ballooning 
At the point of ethanol-induced maximum injury, H&E staining showed 
large inclusions of fat, some hepatocyte ballooning, and mild inflammatory 
infiltrate (Fig. 3.8A). In the recovery phase, ballooning slowly resolved within 72 
hours (Fig. 3.8B), and scattered foci of inflammatory cells surrounding dead 
hepatocytes appeared within 24 hours but disappeared within 48 hours (Fig. 
3.8C). Compared to saline-treated mice, the extent of liver inflammatory cell 
infiltration was significantly lower in mice treated with Anakinra. No significant 
differences were observed in the extent of ballooning. As ballooning provides 
only semi-quantitative assessment of hepatocyte damage, we used serum ALT 
for quantitation of hepatocyte damage. The mean ALT level at the point of 
maximal injury was 250 U/L (Fig. 3.8D), which is approximately two times higher 
compared to levels we observed in previous studies in mice on Lieber-DeCarli 
ethanol diet without acute ethanol binge92,110,164. ALT levels normalized by day 4 
in saline-treated mice and by day 2 in mice treated with Anakinra, indicating that 
inhibition of IL-1 signaling facilitates recovery from liver injury (Fig. 3.8D).   
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Figure 3.8 Treatment with Anakinra facilitates recovery from acute-on-
chronic alcoholic liver injury 
Liver injury was analyzed using H&E staining (A) and hepatocyte death was 
quantitatively evaluated using serum ALT (B). Semi-quantitative scoring was 
performed for histological features of hepatocellular ballooning (0-2) 
(C) and lobular inflammation (0-2) (D). n=3–5 per time point and treatment. 
Numbers in graphs indicate P-values. *P≤.05 vs baseline  
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We further evaluated the role of Anakinra on inflammation by probing for 
neutrophil liver infiltration using myeloperoxidase (MPO) immunohistochemistry. 
We found levels of MPO staining had rapidly normalized by day 1 of recovery 
phase in mice treated with Anakinra and remained low, while saline-treated mice 
maintained elevated levels as late as day 4 (Fig 3.9A,B).  
Lastly, Oil-red-O staining of the liver, that was used to evaluate the 
accumulation of fat, showed significant steatosis at the point of maximal injury 
(Fig 3.9C). In the recovery phase, fat droplets disappeared and steatotic score 
dropped within 24 hours (Fig 3.9D). We observed rapid regression of steatosis 
during the recovery phase which was so fast that we could not evaluate the role 
of Anakinra in this scenario. 
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Figure 3.9 Treatment with Anakinra facilitates recovery from acute-on-
chronic alcoholic liver inflammation and steatosis 
Neutrophil liver infiltration was assessed by MPO immunohistochemistry (A) with 
LPS-injected mouse liver (0.5 mg/kg, 12 h) used as positive control (Pos. 
Control), and positive cells per visual field were quantified, average of five 
images per sample (B).  Steatosis was evaluated by Oil-red-O staining (C) and 
scored semi-quantitatively on a scale from 0-3 (D). n=3–5 per time point and 
treatment. Numbers in graphs indicate P-values. *P≤.05 vs baseline  
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Hepatocyte regeneration 
To evaluate liver regeneration, we stained livers for Ki67, a marker 
expressed by proliferating cells but absent in quiescent cells. Livers harvested 
from mice at baseline and at the point of maximal injury showed minimal Ki67 
signal, indicating minimal proliferative activity and there was no significant 
difference between these two time-points (Fig. 3.10A). Compared to the point of 
maximal injury, increased Ki67 nuclear staining was present in hepatocytes from 
saline-treated mice on days 1 and 2 of recovery. Furthermore, the increase in 
Ki67 was even greater in mice treated with Anakinra (Fig. 3.10A,B). Image 
analysis showed a significant increase in the proportion of Ki67-positive 
hepatocytes on days 1 and 2 of recovery, and this proportion was significantly 
higher in mice treated with Anakinra compared to saline treatment.   
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Figure 3.10 Treatment with Anakinra enhances liver regeneration from 
acute-on-chronic alcoholic liver injury 
WT mice were treated with ethanol diet for 4 weeks and received three 
intragastric gavages of EtOH (5 g/kg) during the last 3 d of ethanol feeding (Max. 
Injury). After day 28, all mice were switched to control diet, and daily treatment 
with Anakinra or saline was initiated (Recovery Phase). Liver regeneration was 
analyzed using Ki67 (A). Quantification of Ki67 signal was performed using 
ImageJ (B). n=3–5 per time point and treatment. Numbers in graphs indicate P-
values. *P≤.05 vs baseline  
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We further tested our hypothesis by evaluating cyclin D1 levels in the liver. 
Cyclin D1 is a nuclear protein required for progression through the G1 phase of 
the cell cycle. Cyclin D1 liver immunohistochemistry staining in murine liver 
sections 24 hours post partial hepatectomy served as a positive control (Fig. 
3.11A). We found that hepatocellular size increased after partial hepatectomy, 
with distinct nuclear and cytoplasmic expression in controls, while ethanol 
administration resulted in a different pattern of expression similar to that 
observed with Ki67 staining. Mice treated with Anakinra had increased levels of 
cyclin D1 protein expression per visual field compared to saline-treated controls 
(Fig. 3.11A,B).  This data indicated that inhibition of IL-1 signaling facilitates liver 
regeneration in ethanol-induced liver injury. The proportion of Ki67-positive 
hepatocytes significantly decreased by day 3 and returned to baseline by day 4 
of recovery both in the Anakinra and saline treated groups, while Anakinra-
treated mice had consistently higher levels of cyclin D1 throughout the recovery 
phase.   
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Figure 3.11 Treatment with Anakinra enhances hepatocyte regeneration 
from acute-on-chronic alcoholic liver injury 
WT mice were treated with ethanol diet for 4 weeks and received three 
intragastric gavages of EtOH (5 g/kg) during the last 3 d of ethanol feeding (Max. 
Injury). After day 28, all mice were switched to control diet, and daily treatment 
with Anakinra or saline was initiated (Recovery Phase). Liver regeneration was 
analyzed using cyclin D1 (A), with murine liver 24-hours post partial hepatectomy 
used as positive control (Pos. Control). Cyclin D1 positive cells were counted per 
visual field, average of five images per sample (B). n=3–5 per time point and 
treatment. Numbers in graphs indicate P-values. *P≤.05 vs baseline   
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Finally, to assess liver size, we analyzed liver mass as a function of 
bodyweight of mice at the time of sacrifice (Fig. 3.12). We found that saline-
treated mice had increased liver size at day 2, the same time-point associated 
with increased hepatocellular ballooning (Fig.3.8A,B). Importantly, Anakinra-
treated mice had an increase in liver size at day 7 of the recovery phase, 
compared to the saline-treated controls. These findings correlate positively with 
the increased enhanced hepatocyte regeneration of mice treated with Anakinra 
(Fig. 3.10, 3.11). 
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Figure 3.12 Liver-to-bodyweight ratios after acute-on-chronic alcoholic liver 
injury  
WT mice were treated with ethanol diet for 4 weeks and received 3 intragastric 
gavages of EtOH (5 g/kg) during the last 3 days of ethanol feeding. After day 28, 
all mice were switched to control diet, and daily treatment with Anakinra or saline 
was initiated. Baseline refers to mice sustained on iso-caloric control liquid diet 
for the duration of the feeding (Week 5, day 7). Mice and excised livers were 
weighed at the time of sacrifice; data presented as fold increase of liver/mouse 
mass (A). n = 3–5 per time point and treatment. *P ≤ 0.05 vs. baseline.   
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Pyroptosis 
When immune cells have inflammasome activation, IL-1β and IL-18 
secretion were not the only signaling molecules observed being excreted. 
Interestingly, release of ATP, HMGB1 and IL-1α release was also observed165-
167. HMGB1 and IL-1α are particularly interesting because they fall under the 
category of alarmins – DAMPs that can have a dual role, with or without post-
translational modifications, when secreted168. Although inflammasome activation 
requires certain caspase activity, such as Caspase-1 or Caspase-11, it wasn’t 
known for some time how exactly Caspase-1 activation was eventually followed 
by cell death. This regulated, necrotic-like cell death dependent on 
inflammasome activation is called pyroptosis, resulting in DAMPs release 
through cell lysis56,169,170. Pyroptosis, however, has not been identified in the 
context of ALD. A recent study created a synthetic model of inflammasome 
signaling in the liver through genetic manipulation with constitutively active 
NLPR3 in hepatocytes171. This resulted in a fibrotic phenotype, along with 
pyroptosis of hepatocytes, as one would expect. The same group has also 
shown an important role of NLRP3 in progression of non-alcoholic steatohepatitis 
(NASH)172, however, this study did not probe for presence of pyroptosis, and the 
inflammasome activation was not shown to be localized to hepatocytes, but 
rather in total liver.  
In our first experiment tracking total number of liver macrophages over a 
period of seven days of ethanol administration, we had identified an initial 
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decrease in macrophage numbers in the liver of adoptive transfer of GFP+ 
macrophages upon initial ethanol exposure, followed by recruitment of more 
macrophages. (Fig. 3.13A-C). One possible explanation was that macrophages 
were initially leaving the liver, possibly to communicate with other immune cells 
for recruitment, and then returning after several hours or days. However, the 
most likely explanation for these observations was that due to inflammasome 
activation, macrophages were undergoing pyroptosis, and through IL-1β 
signaling and sustained DAMP release from hepatocytes, more macrophages 
were recruited. We therefore hypothesized that pyroptosis was taking place in 
liver macrophages upon inflammasome activation after sustained ethanol 
exposure. To test this, we isolated Kupffer Cells and overall liver mononuclear 
cells (LMNC) from ethanol-fed and pair-fed mice after acute-on-chronic ethanol 
administration. We found that there was a decrease in CD45+ cells over all, 
especially in F4/80, CD11b+ cells. Similarly, we observed a decrease in liver 
macrophage numbers after an ethanol binge after ten days of chronic ethanol 
administration (Fig. 3.14A-B).   
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Figure 3.13 Ethanol exposure results in initial decrease of macrophages 
with subsequent increase in the liver  
Mice overexpressing GFP in BM-derived cells were fed Lieber-DeCarli diet and 
sacrificed at indicated time points. Livers were perfused, LMNCs were isolated, 
and analyzed via Flow Cytometry as indicated in the gating strategy (A). 
Percentage of GFP-positive (i.e. BM-derived) inflammatory cells in the liver was 
determined in the CD11b+/F4/80+ population of liver immune cells (B) and (C). 
Cells plotted by side-scatter-area (SSC-A) vs. GFP expression (FITC-A).  
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Figure 3.14 Kupffer cell numbers decrease after acute-on-chronic ethanol 
administration 
WT mice were fed a Lieber-DeCarli diet for 10 days and sacrificed 9 hours after 
an ethanol binge (5 g/kg). Livers were perfused, and LMNCs were isolated. Cells 
were gated for live, CD45+, CD11b+ and F4/80+ expression. Kupffer cells, CD45+ 
F4/80high CD11b+(A); infiltrating macrophages, CD45+ F4/80mid CD11b+(B); 
neutrophils, CD11b+ Ly6G+ (C); and ALT vs neutrophil percent plotted.  
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To test if this decrease in liver macrophages was caspase-dependent 
pyroptosis, we tested inhibition of Caspase-1 activation in a model of ALD. We 
hypothesized that caspase inhibitors would be effective in preventing 
inflammasome activity and subsequent pyroptosis. We administered mice with 
either a pan-Caspase inhibitor, z-VAD-fmk, an FDA-approved Caspase-1 
inhibitor, VX-765, or a necroptosis inhibitor, Necrostatin-1, to target multiple 
pathways of programmed cell death in parallel.  
VX-765 (Belnacasan) is an orally absorbable pro-drug of VRT-043198 
effective against Caspase-1 and -4173-177. Z-VAD-fmk is a cell-permeable inhibitor 
of caspase proteases178-183, including Caspase-1, -3, -8, and -9, all of which have 
been implicated in ALD. Finally, Necrostatin-1 is a RIPK1 inhibitor, needed for 
necroptosis activation184,185.  
We detected a significant decrease in liver injury as measured by serum 
ALT in mice treated with z-VAD-fmk and VX-765 (Fig. 3.15), suggesting that 
Caspase-1 as well as other caspases play a role in furthering ethanol-induced 
liver injury. An absence of change in ethanol-induced liver injury after 
Necrostatin-1 administration suggests that cell death from acute effects are not 
related to necroptosis.  
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Figure 3.15 Protection in liver injury from Caspase inhibition  
Mice were given an acute-on-chronic ethanol diet and sacrificed 4 or 9 hours 
post ethanol binge. Pair-fed mice were sacrificed 9 hours post a sugar binge. 
During the experiment, mice were injected with a pan-Caspase inhibitor (z-VAD-
fmk), a Caspase-1 inhibitor (VX-765), or a necroptosis inhibitor (Necrostatin-1) or 
vehicle. Serum ALT was analyzed as marker for liver injury (A).   
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Gasdermin D as cell executioner 
In 2015, gasdermin D (Gsdm D) was first identified as the executioner of 
pyroptosis. Upon cleavage by Caspase-11 or Caspase-1, gasdermin D is 
cleaved, forming a pore in the plasma membrane of the cell186,187. This quickly 
triggers the necrotic cell death previously identified. Interestingly, the gasdermin 
family of proteins may have a variety of roles associated with apoptosis188. We 
hypothesized that gasdermin D may play a role in directing LMNCs to undergo 
pyroptosis upon ethanol-induced inflammasome activation. To test this, we 
probed for presence of cleaved gasdermin D protein in liver lysate using an 
antibody specific for the N-terminal amino acids 126-138189. We found an 
increase in cleaved gasdermin D in liver 9 hours after a single binge as part of 
acute-on-chronic ethanol administration (10 days) (Fig. 3.16A,B). To test for 
gasdermin D cleavage in a model of alcoholic sepsis, we administered 10 days of 
Lieber-DeCarli ethanol diet followed by an injection of low dose LPS (0.5 mg/kg). 
Interestingly, we found that a single injection of LPS did not lead to gasdermin D 
cleavage, but did accentuate this signal if the LPS injection was administered 
after chronic ethanol (Fig. 3.1C,D). The timing of gasdermin D cleavage, peaking 
at 9 hours post binge, correlates with the peak of inflammasome activity, 
measured 4 hours post binge. It would be expected that cleavage of IL-1β by 
Caspase-1 would be subsequently followed by gasdermin D cleavage.  
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Figure 3.16 Gasdermin D cleavage in ALD  
Mice were given a 10 days Lieber-DeCarli ethanol diet and sacrificed 4 or 9 
hours post ethanol binge. Pair-fed mice were sacrificed 9 hours post a sugar 
binge. Mice were sacrificed, whole cell liver lysate was analyzed via western blot 
for N-terminal gasdermin D cleavage (A) and cleaved gasdermin D (Gsdm D) 
band was quantified using ImageJ (B). WT mice were given Lieber-DeCarli diet 
for 10 days and some mice received a low dose LPS injection (0.5mg/kg) and 
sacrificed 9 hours post LPS injection. Pair-fed mice were sacrificed 9 hours post 
a sugar binge. Mice were sacrificed, whole cell liver lysate was analyzed via 
western blot for N-terminal gasdermin D cleavage (C) and cleaved gasdermin D 
band was quantified using ImageJ (D).       
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Extracellular ASC aggregates 
Based on our findings that pyroptosis of LMNCs indeed occurs in ALD 
through gasdermin D, which is required for IL-1β secretion187, we sought to 
investigate the role of extracellular apoptosis-associated speck-like protein 
containing a CARD) (ASC) and its potential association with pyroptosis. Upon 
inflammasome assembly, ASC (previously known as PYCARD) proteins are 
phosphorylated and polymerize into an enormous intracellular aggregate, 
allowing for the recruitment and activation of Caspase-1190-194.  There have also 
been multiple reports of active Caspase-1 fragments in cell supernatants195-204. 
These reports suggest that a fully active inflammasome assembly is released by 
necrotic cells upon inflammasome activation. Of particular interest, however, is 
ASC itself, which is released and remains active extracellularly205,206. 
Extracellular inflammasome components have been previously identified in the 
serum of patients with cryopyrin-associated periodic syndromes (CAPS), 
associated with abnormally high levels of inflammasome signaling due to gain-of-
function mutations in NLRP3205.  
It is possible that some inflammasome components released by pyroptotic 
cells are further contributing to the inflammatory cascade by being internalized by 
liver macrophages or other cell types such as hepatic stellate cells207,208, and 
even hepatocytes, which have been shown to, at the very least, express 
components of inflammasome signaling171,209. Given these observations, we 
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hypothesized that ethanol-induced inflammasome activation results in ASC 
speck deposits in the liver, furthering the inflammatory cascade.   
Using an ELISA for ASC, we found an increase in ASC protein circulating 
in patients with acute AH compared to healthy controls. We confirmed our results 
via immunoprecipitation of ASC analyzed via western blot from plasma of AH 
patients. To gain a better insight as to the cell type specificity and overall 
expression pattern of ASC in the liver, we analyzed liver sections of cirrhotic 
patients with acute AH via immunohistochemistry for ASC protein. We found 
extremely high levels of ASC protein (Fig. 3.17). We expected to see low levels 
of ASC expression in healthy controls since immune cells will express non-
polymerized ASC under normal, unstimulated conditions. Interestingly, ASC 
expression in diseased patients showed a consistent pattern of massive 
aggregates, most of which appear to be extracellular in nature. This created a 
spotted pattern through the liver, resembling a phenotype I’ll describe as 
Camelopardalis maculae, or spots of a giraffe.  We probed livers from ten 
different diseased patients and this pattern was present in all of them, while 
being consistently absent in all normal livers tested. We tested for specificity of 
the staining by testing three different anti-ASC antibodies from different 
manufacturers, as well as testing non-specific binding of the antibody by using 
livers from ASC-knockout mice.  
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Figure 3.17 ASC aggregates in livers from patients with AH 
Normal and cirrhotic livers from patients with AH were probed for presence of 
ASC protein via immunohistochemistry. Numbers above each box correspond to 
a patient identifying number. Magnification at 400x.        
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Surprisingly, ASC aggregate formation in diseased liver was not exclusive to 
patients with AH. We tested five cirrhotic livers from patients with non-alcoholic 
steatohepatitis (NASH) and all five were also positive for large deposition of ASC 
protein, showing the same Camelopardalis maculae pattern observed in patients 
with AH (Fig 3.18). Although the pathogenic role of inflammasome signaling in 
NASH (reviewed here210) was once controversial, with one prominent study 
reporting that NLRP3 has protective effects 211, several recent reports have 
implicated NLRP3 in the pathogenesis of NASH172,212-214. Our findings correlate 
with the latter group, suggesting an important role of ethanol-induced pyroptosis-
mediated extracellular ASC in an inflamed, fibrotic liver. 
  
 177 
Figure 3.18 ASC aggregates in livers from patients with NASH  
Normal and cirrhotic livers from patients with NASH were probed for presence of 
ASC protein via immunohistochemistry. Numbers above each box correspond to 
patient identifying number. Magnification at 400x.  
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NLRP3 inhibition using MCC950 
The identification Camelopardalis maculae phenotype in AH patients is 
important not just for the extent of expression in diseased patients, but also 
because of what this implies in term of future therapies. As mentioned earlier, the 
Defeat Alcoholic Steatohepatitis (DASH) U01 clinical trial for severe AH 
incorporates the use of IL-1Ra, which inhibits IL-1 signal propagation by inhibition 
of IL-1R in the presence of Caspase-1 activity and cleaved IL-1β. However, using 
IL-1R as a therapeutic target implies permissible inflammasome activity, with 
concomitant pyroptosis, DAMPs release and ASC aggregate formation in the 
liver. IL-1Ra therapy therefore is best at preventing the inflammatory cascade 
that results from feed-forward mechanisms from inflammasome signaling in the 
diseased state, but only if driven through IL-1 signaling, but not by the branching-
off pathways. While IL-1Ra has shown promising results in animal models in 
treatment of ALD, it seems perhaps prudent to consider an alternate approach to 
target inflammasome signaling upstream of its activation. For this reason, we 
decided to test the efficacy of MCC950, an NLRP3-specific small-molecule 
inhibitor, as a potential novel therapy.  
In an acute model of early ALD, we administered three ethanol binges over a 
period of three days. Mice were sacrificed 4 hours after the final binge, for peak 
inflammasome signal in the liver, but not for overall liver injury. Mice that were 
pre-treated with MCC950 had reduced levels of serum ALT (Fig 3.19A). At this 
time-point, where mice were sacrificed 4 hours post the final binge, the 
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morphological features in liver histology were not drastically different (Fig. 
3.19B). We did detect a significant reduction in liver inflammasome activation, 
with reduced levels of Caspase-1 and IL-1β cleavage (Fig. 3.19C). We decided 
to test this NLRP3 inhibitor in a more robust model of liver injury using the 
standard 4 week Lieber-DeCarli model of chronic ALD. However, we tested 
MCC950 as a potential therapy to an already established injured liver, not as a 
preventative approach where the compound is administered through the feeding.  
We found that mice treated with MCC950 had an effective reduction in liver injury 
compared to their ethanol-treated group (Fig 3.19D). This suggests that NLPR3 
inhibition via a small molecule inhibitor is an effective therapy in a murine model 
of ALD.  
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Figure 3.19 In vivo inhibition of ethanol-induced NLRP3 inflammasome with 
MCC950 
WT mice were administered three doses of acute ethanol. MCC950 was 
administered at a dose of 5 mg/kg/day, i.p., to some mice 30 min. prior to ethanol 
binge. Liver injury was assessed by serum ALT (A) and H&E liver histology (B). 
Efficacy of inhibition of inflammasome signaling was assessed by measurement 
of Caspase-1 and IL-1β cleavage in liver by western blot and quantified by 
ImageJ (C). WT mice were fed a 4 week Lieber-DeCarli ethanol diet. After two 
weeks, some mice received daily injections of MCC950. At the conclusion of the 
experiment, liver injury was assessed by serum ALT (D). Acute ethanol model: n 
= 3–5 per time point and treatment; chronic ethanol model: n = 6-10 mice. *P ≤ 
0.05 vs. baseline; ***P ≤ 0.0001 vs. DMSO-treated ethanol group. 
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Inflammasome signaling through extracellular vesicles 
It has been reported by our group and others that LMNCs communicate 
through exchange of cytoplasm via extracellular vesicles, and this cargo is pro-
inflammatory in ALD215-218. Based on these studies and on our previous findings 
of circulating ASC in plasma from patients with AH, we hypothesized that ASC 
and other inflammasome components may be present in extracellular vesicles 
after ethanol exposure. To test this, we stimulated THP1 monocytes with PMA for 
48 hours to induce a macrophage phenotype and then stimulated with LPS and 
Nigericin, a potent and well-studied NLRP3-inflammasome activator. We isolated 
extracellular vesicles from the supernatant for presence of ASC. At the same 
time, we used the cell pellet as positive control for the presence of ASC protein in 
our western blot analysis. We detected the presence of ASC protein in lysate 
from extracellular vesicles isolated from supernatant of stimulated cells, which 
was absent from non-treated cells. (Fig. 3.20) Although this data is still 
preliminary, it suggests an ability of cell-to-cell communication of inflammasome 
components via extracellular vesicles in an in vitro system.   
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Figure 3.20 THP1-derived ASC in extracellular vesicles  
Human monocyte cell line was stimulated with PMA to induce a macrophage 
phenotype (48 hours). Cells were then stimulated with LPS (10ng/mL) and 
nigericin to induce inflammasome activation. Supernatant and cell pellet were 
collected. Extracellular vesicles were purified using ExoQuick precipitation 
overnight and analyzed via western blot for the presence of ASC protein.  
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Figure 3.21 Summary of NLRP3 inflammasome activation in ALD  
ATP and uric acid are released by ethanol-damaged hepatocytes. Kupffer cells 
are activated by LPS from the gut (signal 1), which license inflammasome 
assembly. P2X7-mediated ATP and/or uric acid (signal 2) activate the 
inflammasome upon recognition by NLRP3, which activates Caspase-1. Active 
Caspase-1 cleaves pro-IL-1β into its mature and active form, which signals 
through the IL-1 receptor.  
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Spleen Tyrosine Kinase 
Spleen tyrosine kinase (SYK) is a regulator of signal transduction with 
broad reach across multiple signaling sequences. SYK is part of the Src-family 
and is a 72-kDa non-receptor tyrosine kinase, initially identified in hematopoietic 
cells219. SYK has recently been identified as a therapeutic target in hepatocytes 
in hepatitis C virus infection220. SYK is expressed in the cytoplasm and nucleus 
of hepatocytes, immune cells and other cell types221. SYK functions mainly in the 
transmission of inflammatory downstream signals through components of innate 
immunity. Specifically, SYK modulates activation of TLRs, which are among the 
first receptors to be activated in response to pathogen-associated molecular 
patterns (PAMPs)222. Upon activation, SYK regulates downstream signaling 
events that drive inflammatory pathways in innate immunity. Inhibition of SYK in 
macrophages reduced signaling through TLR4 and reduced production of IL-6, 
MCP-1, TNFα, and cleaved IL-1β222,223. SYK also plays an important role in 
hepatic neutrophils, an important pro-inflammatory cell type in alcoholic hepatitis 
(AH)92, through β2 integrin (CD18)-mediated extravasation of neutrophils to 
inflammatory lesions224. Given the broad cellular expression pattern of 
SYK219,220,225, as well as its diverse cellular regulatory role of signaling pathways 
associated with ALD226, we hypothesized that SYK may constitute a major 
regulator in the pathophysiology of ALD and as such, might serve as a novel 
therapeutic target. 
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Specifically, SYK regulates inflammasome activation leading to production of 
active IL-1β and IL-18223,227. We found an increase in phosphorylated SYK in 
liver lysate and in LMNCs isolated from ethanol-fed mice228. More importantly, 
mice that received daily injection of SYK inhibitor had reduced levels of Caspase-
1 cleavage and secretion of IL-1β into circulation compared to vehicle treated 
mice164. Together, this data suggests that SYK inhibition is a potent intervention 
to prevent inflammasome activation, likely through TLR4, as well as IL-1β 
processing in different stages of ALD, similar to its role in other inflammatory 
conditions. 
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Figure 3.22 Inhibition of SYK activation suppressed alcohol-induced 
inflammasome activation and IL-1β production in two murine models of 
ALD  
WT mice were given a 10 day Lieber-DeCarli ethanol diet and sacrificed 9 hours 
post ethanol binge (‘Moderate ASH’); Pair-fed mice were sacrificed 9 hours post 
a sugar binge (A-C) or 4 weeks of Lieber-DeCarli diet (‘Chronic EtOH’). Mice 
received daily intraperitoneal administration of SYK inhibitor (‘SYK Inh.’) or 
vehicle (‘Veh.’). Total RNA was extracted from mouse livers and assessed by 
RT-qPCR for IL-1b mRNA normalized to 18S. (A). Whole-cell liver lysate was 
probed for the presence of cleaved Caspase-1 protein, and quantified using 
ImageJ. (B). Serum samples from mice were analyzed by via ELISA for IL-1β 
(C,D). A P value <0.05 was considered statistically significant by analysis of 
variance for 6-8 mice per experimental group (*P < 0.05 compared to baseline; 
#P < 0.05 compared to EtOH 1 vehicle group).  
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Figure 3.23 Summary of SYK signaling in ALD  
This illustration summarizes our findings on SYK signaling from various models 
of ALD. In the first panel, SYK modulates ERK phosphorylation and NFκB 
activation. In the second panel, SYK regulates inflammasome signaling by 
controlling TLR4 and NLRP3 activation. In the third panel, SYK controls changes 
in ROS- and MCP-1-dependent gene expression in hepatocytes resulting in 
decreased free fatty acid oxidation and increased free fatty acid synthesis. In the 
fourth panel, SYK regulates TBK1 and IRF3 activation through TLR4, resulting in 
increased Caspase-3 cleavage.  
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CHAPTER FOUR: BILE ACID AGONIST SIGNALING 
FXR and TGR5 signaling      
Role as transcription factor 
Bile acids (BAs) act as signaling molecules, activating two dedicated 
receptors: farnesoid X receptor (FXR), a member of the nuclear receptor 
superfamily of transcription factors, and transmembrane G protein-coupled 
receptor 5 (TGR5)229. FXR (BA receptor NR1H4) and TGR5 (also known 
as G-protein coupled bile acid receptor 1) regulate BA synthesis, lipid, 
glucose and energy homeostasis, as well as inflammation and fibrosis, all 
of which are important components in the pathogenesis of nonalcoholic 
steatohepatitis (NASH) and ASH230,231. Recent reports have highlighted 
the potential of synthetic agonists for these receptors in various liver 
disease models and in the treatment of different chronic liver 
diseases232,233. The FXR agonist obeticholic acid (OCA, also known as 
INT-747) has been recently approved for the treatment of primary biliary 
cholangitis (PBC), a chronic autoimmune liver disease234. This drug has 
also shown promising results in the treatment of NASH in a Phase 2 
trial235, demonstrating anti-inflammatory and anti-fibrotic effects in the 
liver, and is currently in a Phase 3 clinical trial in NASH (ClinicalTrials.gov 
identifier, NCT02548351; sponsored by Intercept Pharmaceuticals). 
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Although NASH and ASH have distinct etiologies, both liver diseases have 
overlapping pathogenic mechanisms, including steatosis, inflammation and liver 
injury. Here we have tested the hypothesis that FXR and/or TGR5 agonists may 
be therapeutic in the treatment of early ASH in mice. 
Bile receptor agonists 
BA receptor agonists attenuate liver injury in acute ethanol liver injury 
We found that in the binge ethanol injury model, pre-treatment with OCA 
and INT-777 resulted in decreased hepatic microvesicular steatosis as seen in 
H&E histology, while the FXR/TGR5 dual agonist, INT-767, resulted only in mild 
improvement of these histological features and liver injury (Fig. 4.1A,D). We then 
analyzed liver lipid accumulation via Oil-Red-O staining and found reduced levels 
in the percent of positive Oil-Red-O area (Fig. 4.1B,C) with each BA receptor 
agonist treatment, albeit only OCA showed a statistically significant reduction 
compared to vehicle pretreatment. The superior protection from steatosis by 
OCA after acute ethanol administration correlated positively with decreased 
serum ALT levels, suggesting that in this model of early ethanol-induced liver 
injury, OCA protects from liver damage and steatosis. In the acute binge ethanol 
model, mice pre-treated with the FXR agonist OCA had significant protection 
from liver injury, as measured by serum ALT, compared to ethanol-binged mice 
treated with vehicle.  
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Figure 4.1 Bile acid agonists attenuate liver injury and microvesicular 
steatosis after acute ethanol injury  
WT mice treated with bile acid agonist or vehicle were exposed to ethanol or 
sugar binges. Liver injury and microvesicular steatosis was assessed by H&E 
histology on liver sections (A-C) and serum ALT (D). Steatosis was assessed by 
Oil-red-o staining (B), and percent-positive staining was quantified by ImageJ 
from the average of five random images per sample (C). P values. *P < 0.05 
compared to baseline, **P < 0.001 compared to baseline,  #P < 0.05 compared 
to vehicle-treated ethanol group. N=5 for Pair-fed, 10 for ethanol, per treatment. 
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BA receptor agonists attenuate liver injury and steatosis in early ALD 
We similarly analyzed mouse liver sections via H&E histology and Oil-
Red-O staining after prolonged ethanol administration that resulted in liver injury 
and steatosis compared to pair-fed mice (Fig. 4.2A,B). Mice treated with vehicle 
plus ethanol had substantial accumulation of macrovesicular steatosis (Fig. 
4.2A), a phenotype not present in the acute liver injury model. Furthermore, H&E 
staining showed that mice treated with OCA, INT-767, or INT-777 had decreased 
hepatic macrovesicular steatosis in the liver compared to the vehicle-treated 
ethanol group. Likewise, Oil-Red-O staining showed a significant decrease in 
steatosis after treatment with each of the three BA receptor agonists (Fig. 
4.2B,C). 
To test if changes in serum ALT correlated with changes in liver structure, we 
performed liver histology. Prolonged ethanol administration resulted in liver injury 
indicated by elevated serum ALT (Fig. 4.2D). Interestingly, OCA treatment did 
not attenuate liver damage after 12 days of chronic ethanol administration. In this 
prolonged alcohol feeding model that causes features of early alcoholic liver 
disease, only treatment with the FXR/TGR5 dual agonist INT-767 reduced serum 
ALT levels significantly compared to the vehicle-treated ethanol group.  
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Figure 4.2 Bile acid agonists attenuate liver injury and macrovesicular 
steatosis after prolonged ethanol injury  
WT mice treated with bile acid agonist or vehicle were exposed to 12 days of 
prolonged ethanol or pair-fed liquid diet. Liver injury and macrovesicular steatosis 
was assessed by H&E histology on liver sections (A-C) and serum ALT (D). 
Steatosis was assessed by Oil-red-o staining (B), and percent-positive staining 
was quantified by ImageJ from the average of five random images per sample 
(C). P values. *P < 0.05 compared to baseline, **P < 0.001 compared to 
baseline,  #P < 0.05 compared to vehicle-treated ethanol group. N=5 for Pair-fed, 
10 for ethanol, per treatment. 
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Regulation of NLRP3 
Ubiquitination of NLRP3 by PKA 
We hypothesized that perhaps BA receptor agonists were inhibiting 
inflammasome signaling. To test this, we first probed for Caspase-1 activity in the 
liver. We found that there was a decrease in Casp-1 cleavage (Casp-1p10), in 
both acute and prolonged ethanol models, indicative of inflammasome activity 
(Fig.4.3A,B). To test if the mechanism by which the inflammasome was inhibited 
was through the recently reported activation of protein kinase A (PKA), activated 
by cyclic AMP, resulting in ubiquitination of NLRP3236. Our lab has previously 
shown that the NLRP3 sensor is a key driver of inflammation in alcoholic liver 
disease through activation from uric acid and ATP, released by damaged 
hepatocytes163,237. We found an increase in phosphorylated PKA substrate, 
suggesting of PKA activity, especially with the TGR5 agonists (Fig. 4.3C). To test 
if PKA activity resulted in increased ubiquitination of NLRP3, we performed 
immunoprecipitation of NLRP3 and probed for ubiquitin. We found an increase in 
ubiquitin-tagged NLPR3, especially with INT-767, the dual agonist (Fig. 4.3D).  
Taken together our data here indicate that BA receptor agonists lower steatosis 
and improve liver pathology in ALD models by targeting NLRP3 inflammasome 
signaling as well as reducing steatosis in ALD.   
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Figure 4.3 Bile acid agonists regulate NLRP3 inflammasome via PKA  
WT mice treated with bile acid agonist or vehicle were exposed to ethanol or 
sugar binges, or to 12 days of prolonged ethanol or pair-fed liquid diet. Effects on 
inflammasome activity were assessed by probing for Caspase-1 cleavage in liver 
lysate by western blot in the acute (A) and prolonged ethanol feeding model (B). 
protein kinase A (PKA) activity in the prolonged ethanol model was assessed by 
probing for phospho-PKA substrate in liver lysate (C). Ubiquitination of NLRP3 
was assessed by immunoprecipitation of NLRP3, followed by probing of ubiquitin 
protein by western blot (D).  
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Regulation of steatosis through bile acid receptors 
In recent years, the role of FXR in lipid and glucose metabolism has been 
explored238-241. FXR activation lowers plasma and liver triglyceride by enhancing 
plasma triglyceride clearance 242 and repressing sterol regulatory element–
binding protein (SREBP) 1c-mediated hepatic lipogenesis243. Our data in Figure 
4.4A-C shows a significant reduction in FASN protein expression in the liver after 
treatment with FXR/TGR5 agonists. Therefore, it is likely that BA receptor 
agonists likely affect fatty acid synthesis pathways directly. The lipogenic and 
lipolytic changes correlate with previously described reversal in pathology 
associated with the development of ALD164,228.  
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Figure 4.4 Bile acid agonists decrease steatosis through FASN 
downregulation  
WT mice treated with bile acid agonist or vehicle were exposed to ethanol or 
sugar binges, or to 12 days of prolonged ethanol or pair-fed liquid diet. Fatty acid 
synthase expression was assessed by probing for FASN in liver lysate by 
western blot in the acute (A) and prolonged ethanol feeding model (B). Individual 
western blots are shown in (C), where acute is shown first followed by prolonged 
ethanol administration, listed in groups according to treatment. Quantification 
was done via ImageJ.  
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Discussion 
Notwithstanding significant advances in understanding the pathogenesis of ALD, 
very few treatment options are approved22,244,245. Here we tested the therapeutic 
potential of BA receptor agonists in two mouse models of alcoholic liver injury. 
Our data show that in the acute liver injury model, OCA was more effective 
compared to the two other agonists, while in the chronic or early ALD model the 
dual FXR/TGR5 agonist, INT-767, shows better therapeutic efficacy compared to 
OCA and INT-777.  
FXR and TGR5 play key roles in ALD by modulating BA metabolism, lipid 
and glucose metabolism, as and well as liver regeneration246. Alcohol 
consumption induces hepatic lipid accumulation, immune cell infiltration and 
increases oxidative stress. More importantly, chronic alcohol consumption results 
in increased BA pool and decreased excretion of BA, suggesting that alcohol 
consumption may affect enterohepatic circulation247,248. However, acute alcohol 
exposure has been reported to induce BA synthesis in humans and primary 
hepatocytes249,250. Moreover, OCA has been shown to reduce bacterial 
translocation251. Hence, we chose to test both acute and prolonged alcohol 
exposure models.  Treatment with OCA, INT-767, or INT-777 was effective in 
reducing ethanol-induced steatosis after acute or chronic ethanol administration. 
However, only mice treated with FXR agonist OCA showed protection from acute 
binge ethanol-induced liver injury, whereas mice treated with the dual agonist 
INT-767 showed liver protection after chronic ethanol exposure. Our findings 
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demonstrate that treatment with FXR and/or TGR5 agonists results in improved 
biochemical and histological features of early ALD with varying degrees of 
efficacy depending on the mode of ethanol administration. 
BAs repress the transcription of cytochrome P450 7A1 (CYP7A1), which 
catalyzes the rate-limiting step in BA biosynthesis252. CYP7A1 is the rate-limiting 
enzyme involved in BA synthesis from cholesterol, and the negative feedback 
loop resulting in decreased bile acid synthesis may indirectly result in decreased 
steatosis. Goodwin et. al. showed that FXR ligand treatment induces expression 
of small heterodimer partner 1 (SHP-1), an atypical member of the nuclear 
receptor family253. SHP-1 represses expression of CYP7A1 by inhibiting the 
activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor that is 
known to regulate CYP7A1 expression positively. In our models, pre-treatment 
with OCA and INT-767, both of which signal through FXR (but not INT-777), 
showed increased SHP1 and decrease in CYP7A1 mRNA expression, confirming 
that administration of these FXR agonists has a measurable effect in the liver of 
mice undergoing alcohol-induced liver injury.  
We assessed the effect of FXR/TGR5 agonists in protecting against the alcohol 
induced inflammation. Although there was no impact on TNFα and MCP-1 in both 
models of alcoholic liver injury, the IL-1β mRNA was consistently reduced in both 
models of ethanol administration. This suggests that bile acid agonists may play 
a role in repression of inflammasome signaling, a key driver of inflammation in 
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ALD237. This finding was further supported by the recent report identifying that 
bile acids negatively regulate the NLRP3 inflammasome236.  
Together, our study based on two murine models of ethanol administration 
are supported by a report in which FXR agonist (6ECDCA) treatment resulted in 
decreased hepatic steatosis and oxidative stress in a different model of ethanol-
induced liver injury (ethanol combined with a low-protein diet)254. This finding by 
Lívero et al. suggests that reduced lipid accumulation was mediated by FXR 
regulation of FASN and sterol regulatory element-binding protein (SREBP1C, 
also referred to as Srebpf1) expression255. Our findings here demonstrate that 
FXR/TGR5 activation ameliorates murine alcoholic liver disease and thus provide 
the first evidence of the therapeutic potential of the FRX/TGR5 agonists in 
treatment of alcoholic liver disease.  
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CHAPTER FIVE: DISCUSSION 
Targeting IRF3 in disease 
In the liver, IRF3 is activated by STING, an ER resident protein, in the 
early phase of liver injury. There are several known intracellular dsDNA sensors 
that activate STING signaling in response to viral infection. The cyclic 
dinucleotide 2’3’-cGAMP, synthesized by the dsDNA cytosolic sensor cGAMP 
synthase (cGAS), activates STING. We identified cGAS as key activator of IRF3 
in the early phase of liver injury from ethanol exposure. We specifically identified 
the role of cGAS most prevalent during the acute phase of an acute-on-chronic 
liver injury. Interestingly, cGAS-KO mice had comparable liver injury to WT 
during ten days of chronic ethanol administration, suggesting that the 
involvement of cGAS and STING is predominantly during the early phase of liver 
injury, after which other overlapping IRF3 activators, such as TLR4, may play a 
more important role. To test if STING and IRF3 activation was dependent on 
mitochondrial (mt) DNA released into the cytoplasm and circulation, we 
measured mtDNA in plasma. Ethanol binge in mice results in increase in 
circulating mtDNA at two and four after the binge. Human cirrhotic livers had 
increased oxidative DNA damage, as measured by 8-OHdG 
immunohistochemistry. Further testing by immunofluorescence staining revealed 
8-OHdG staining to be cytoplasmic and not nuclear. To test if mitochondrial DNA 
was responsible for ethanol-induced IRF3 activation, we depleted Huh7 cells, a 
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human hepatoma cell line, of mtDNA by incubation with ethidium bromide for four 
weeks. We found that mtDNA-depleted cells had no IRF3 phosphorylation from 
ethanol in vitro, compared to WT Huh7 cells.  
Previous studies described the role of STING activation in viral infections 
in immune cells29,36,256-258. In hepatocytes, we demonstrated earlier that STING 
and IRF3 mediate the pathogenesis in alcoholic liver disease, a role independent 
of microbial components110. In the present study, our data demonstrate a 
hepatocyte-specific role of STING and IRF3 in mediating hepatic apoptosis as an 
early event in the development of liver fibrosis.   
Hepatocytes are responsible for metabolism and for detoxifying portal blood, 
which can be rich in bacterial products. For this reason, innate immunity plays an 
important role in the liver; even though this organ is rich in immune cells, 
parenchymal cells have an abundance of receptors and are capable of initiating 
immune signaling259-262. In our study, TBK1-mediated ER stress was detected 
early after ethanol or CCl4-administration only in hepatocytes and not in LMNCs.  
Regulated IRE1-dependent decay of mRNA (RIDD), a key component of 
the unfolded protein response, results in degradation of viral mRNA transcripts 
and spliced Xbp1115,263. However, there are multiple lines of evidence suggesting 
that IRF3 activation can result from other forms of noninfectious cell damage that 
involve Xbp1 splicing123,124,264. Here we show that STING activation may provide 
the link between induction of ER stress and IRF3. Moreover, the rapid nature of 
the phosphorylation of IRF3 and Xbp1 splicing in our experiments due to an 
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acute CCl4-induced liver injury underscores the importance of STING and its 
location in the ER. Altogether, activation of STING and IRF3 may be targeted 
therapeutically via protein folding chaperone or ER stress inhibitors, such as 4-
PBA or TUDCA. Our novel in vivo data demonstrate a potential for attenuating 
liver injury and associated liver inflammation through attenuation of ER stress. It 
would be beneficial to assess if other forms of liver injury similarly involve ER 
stress and subsequent activation of IRF3. We tested a separate model of fibrosis 
using the carbon tetrachloride model and found a similar IRF3- and STING-
driven phenotype, but multiple varies of approaches would be better. For 
example, given the similarities between NASH and ASH, it is possible that cGAS 
and STING play at least a partial role in fatty liver disease. It would be important 
to assess this carefully, since the subtle and short-lived signal of IRF3 
phosphorylation could easily lead to false-negative results and incorrect 
interpretation of the data.  
Viral infections as well as noninfectious injuries are associated with 
induction of cell death signals, emphasizing the importance of the BH3-domain 
within IRF3 as responsible for its pro-apoptotic properties in the mitochondria. It 
is also possible that ethanol or CCl4-induced cell death signaling from STING 
activation of IRF3 and BAX may trigger ER membrane permeability265 in addition 
to the effects on the mitochondrial membrane integrity.  
Pro-apoptotic signaling may play a beneficial role in the resolution of 
inflammation after liver injury, specifically when it is targeted to infiltrating 
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immune cells such as neutrophils266. Uncontrolled parenchymal apoptosis, 
however, although typically controlled and tightly regulated, may be the tipping 
point responsible for subsequent necrosis. Our data suggest that overwhelming 
levels of IRF3-mediated apoptosis may eventually lead to a form of secondary 
necrosis. Taken together, our data provides strong evidence that inhibition of 
parenchymal apoptotic signaling is sufficient to reduce necrosis and amplified 
liver damage.  
In conclusion, our study builds on the previous paradigm of ALD. The liver 
damage, ER stress and death of hepatocytes is mediated by the engagement of 
the ER adaptor protein, STING, with phosphorylated IRF3, resulting in activation 
of the mitochondrial pathway of hepatocyte death. As such, fibrosis observed in 
ALD is more than a pathology strictly driven by inflammation. Rather, hepatocyte 
death appears to be a separate key component in the process of liver fibrosis. In 
addition, as summarized in Figure 3.23, propagation of cGAS-mediated cyclic 
dinucleotides via hepatic gap junctions allows for amplification of liver injury. This 
was abrogated with use of the small-molecule inhibitor 2-APB.  
For future direction, I hypothesize that it is perhaps not IRF3 
phosphorylation but rather merely its association with STING and TBK1 that 
license its pathogenic effect. To test if this is mediated by its BH3-domain or 
through its phosphorylation, I propose creating a IRF3-mutated mouse in which 
its BH3 motif has been mutated, but its phosphorylation sites remain intact. The 
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use of such mice would help elucidate the contribution of its association with Bax 
from its phosphorylation and activation.  
  
Targeting Inflammasome activators 
Ethanol cause release of damage-associated molecular patterns (DAMPs) 
from damaged cells. We studied if hepatocyte-derived DAMPs were ligands 
needed for inflammasome activation. Our lab previously showed that ethanol 
exposure results in inflammasome activation and maturation of interleukin (IL)-
1β, a key pro-inflammatory cytokine in ALD.  Oligomerization of the adaptor 
protein ASC (Apoptosis-associated speck-like protein containing CARD) is 
essential for inflammasome activation. Upon inflammasome activation, Caspase-
1 is activated which leads to cleavage of pro- IL-1β into active IL-1β. IL-1β has 
been shown to be required for the development of alcohol-induced liver 
inflammation. Inhibition of IL-1 signaling with Anakinra, an IL-1R antagonist, is 
therapeutic in a mouse model of ALD. Extracellular ASC ‘specks’ that retain 
bioactivity in vitro are released during pyroptosis, a caspase-1 mediated cell 
death.  However, the role of ethanol-induced pyroptosis and extracellular ASC 
has not been identified in ALD. 
We found that ATP and uric acid are two essential DAMPs released by 
damaged hepatocytes, and not liver mononuclear cells, upon exposure to 
ethanol. These DAMPs activate the inflammasome through NLRP3 sensor. 
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Using various genetic knockout and transgenic mice, we identified that uric acid 
and ATP signaling are needed for inflammasome signaling in an in vivo murine 
model of ALD. Moreover, therapeutic intervention in mice with allopurinol or 
probenecid, two FDA-approved compounds that promote secretion of uric acid, 
are effective in treating inflammation and liver injury associated with ALD. When 
dissecting the early events associated with liver injury and inflammation, we 
found that inflammasome signaling further augments hepatocyte injury and 
DAMP release in vivo, in a feed-forward loop. Interestingly, inhibition of IL-1 
receptor, using Anakinra, enhances hepatocyte regeneration and recovery from 
ethanol-induced liver injury. We have also identified MCC950 as a viable 
therapeutic approach in targeting NLRP3 activation in vivo. The use of MCC950 
poses the potential benefit over Anakinra at preventing pyroptosis and 
subsequent gasdermin D cleavage. This is especially important given our new 
findings of extracellular ASC, in circulation and as liver aggregates. 
We analyzed plasma of healthy volunteers and patients with acute 
hepatitis for the presence of ASC protein. Acute hepatitis patients had increased 
soluble ASC protein in the circulation, as measured by ELISA and confirmed with 
immunoprecipitation. On immunohistochemistry, all ten livers from patients with 
alcohol-induced cirrhosis but none of the controls had extensive ASC aggregates 
in extracellular spaces. Using immunofluorescence, we observed extracellular 
ASC aggregates and ASC oligomers with immunoprecipitation in mouse livers 
with acute hepatitis. We hypothesized that extracellular ASC was dependent on 
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liver macrophages undergoing pyroptosis, a necrotic form of inflammasome-
dependent programmed cell death. We found increased ethanol-induced 
pyroptosis and apoptosis indicated by a decrease in AnnexinV-positive 
macrophages from mice pre-treated with Caspase-1 or pan-Caspase inhibitors, 
respectively. Pre-treatment with a necroptosis inhibitor had no effect on cell 
death. Moreover, pre-treating mice with MCC950, an NLRP3 inhibitor, reduced 
levels of Caspase-1 activity, macrophage pyroptosis and steatohepatitis in acute 
hepatitis in mice. Finally, we detected an increase of cleaved Gasdermin D, the 
trigger needed for Caspase-1-mediated pyroptosis, in human cirrhotic livers and 
in mouse livers with alcoholic hepatitis.  
 A recent study by our group focused on targeting upstream activators of 
the inflammasome by daily administration of allopurinol or probenecid (100 
mg/kg), two FDA-approved medications for the treatment of hyperuricaemia in 
patients with gout that decrease urate through differing pathways152. Allopurinol 
is a free radical scavenger and an inhibitor of xanthine oxidase267, an enzyme 
required for uric acid synthesis. Probenecid promotes renal excretion of uric acid. 
Both therapies effectively lowered serum and liver uric acid levels, as well as 
protected from ethanol-induced inflammation, liver injury and steatosis in a 
mouse model of chronic alcoholic steatohepatitis237. 
Our findings of allopurinol administration being protective from ethanol-
mediated liver injury in mice is supported by a previous study by Kono H., et al. in 
2000 using the Tsukamoto and French model in rats153. Interestingly, our results 
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indicate that probenecid provided superior protection from ethanol compared to 
allopurinol. This is likely due to probenecid’s inhibition of ATP signaling via 
pannexin-1 channels154, on top of its promotion of uric acid secretion, thus 
providing a two-pronged approach targeting upstream activators of the 
inflammasome. 
In addition, recombinant uricases have been used in the treatment of gout152. 
Interestingly, in a genetic model mimicking recombinant uricase therapy, our 
group found attenuation of inflammation and liver injury from chronic ethanol 
administration in transgenic mice overexpressing two forms of uricase237. As 
such, it is plausible that recombinant uricase, in combination with other drugs, 
may provide as a viable therapy for treatment of alcoholic steatohepatitis.  
Increasing evidence suggests that cumulative danger signals contribute to 
inflammasome activation in NASH. Gut-derived microbial danger signals, such as 
LPS and/or bacterial DNA, are likely to provide inflammatory signals. In addition, 
as a result of hepatocyte damage, there are several sterile inflammatory signals 
in NAFL and NASH to provide the second signal for inflammasome activation. 
These sterile signals include but are not limited to fatty acids, uric acid, ATP, 
HMGB1 and likely other factors268. For this reason, it is especially important be 
mindful of the potential contribution of the microbiome to the inflammatory 
microenvironment in the liver. Early on, we established a standard operating 
procedure of exchanging bedding of mice between groups to help minimize 
contributions from microbiota. We also ensured that all of our WT mice, which 
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were purchased through Jackson Laboratories, would have at least four to five 
days to acclimate in our mouse facility. This would help their microbiome reach 
equilibrium with our genotype-specific mouse colony that we tested. We used 
littermate control mice for our transgenic mouse studies, which is considered 
best practice. The decision was made that having gender and age-matched 
controls served as a higher priority than having littermate controls. Due to 
limitations on space within our animal facility and prohibitive costs associated 
with rearing our own WT controls, it was not possible for all other mouse 
experiments to use have littermate, age- and gender-matched controls.  
On the topic of inflammation, IL-1β, after engaging the IL-1 receptor (IL-
1R), amplifies pro-inflammatory cytokine production including IL-1β, TNFα , 
MCP-1, and IL-6145. In addition, IL-1β propagates effects that drive to 
pathological features associated with alcoholic liver disease. Specifically, IL-1β 
promotes steatosis, hepatocyte death, liver fibrosis and inhibits hepatocyte 
regeneration64,93,144. All of these biological effects of IL-1β and IL-1R activation 
are blocked by the naturally occurring, endogenous IL-1 receptor antagonist (IL-
1ra). Anakinra is a recombinant version of IL-1RA that blocks the effects of IL-1β 
by inhibiting the binding of IL-1β to IL-1R, was FDA-approved for treatment of 
moderate to severe rheumatoid arthritis (RA) in 2001, and is used also in patients 
with Still's disease among other auto-inflammatory diseases269-271. However, 
given the potential role of post-pyroptotic signaling, the efficacy of MCC950 
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compared directly with Anakinra is an important future step to undertake to 
prevent NLRP3 activation, upstream of IL-1R.  
For future direction, it is important to assess in more detail the role of ACS 
specks. For this, I would recommend the use of a highly inflammatory model 
such as the 4-week plus three-binge model, where plasma is isolated at various 
time-points after the final binge. The best mice to use for these experiments 
would be ASC-GFP transgenic mice developed by Dr. Doug Golenbock. 
Visualizing ASC speck formation from Kupffer Cells and macrophages isolated 
from liver and circulation, respectively, using the Imagining Flow Cytometry 
technology from Amnis FlowSight would be the perfect tool for these 
experiments. It would be critical to assess the role of Gasdermin D in this model, 
and directly compare the role of Anakinra in parallel to MCC950 or VX-765 in 
attenuating Gasdermin D cleavage. I hypothesize that MCC950 and VX-765 
would both provide superior protection from Gasdermin D cleavage and ASC 
speck formation than Anakinra due to their ability to inhibit inflammasome 
activation rather than its mere amplification.  
Potential for role of bacterial dinucleotides 
I hypothesize that bacterial messenger molecules may activate IRF3 early 
after ethanol administration. Based on our previous findings that serum endotoxin 
levels increase early, peaking between one to two hours, and that 
phosphorylation of IRF3 peaks between two and four hours, along with the 
 221 
detection of 16S bacterial DNA in human serum after ethanol consumption272, we 
hypothesize that c-di-GMP, cyclic dinucleotides synthesized by bacteria may 
pass through  the lining of the gut along with LPS. This might explain the 
progression of early phosphorylation of IRF3 in hepatocytes concurrent with 
endotoxin infiltration into systemic circulation and the liver. Ultimately these 
events are followed by hepatocyte death and liver inflammation, indicated by 
increased ALT and TNFα, IL-1β, and MCP1, peaking at eight hours.  For this 
reason, I hypothesize the detection of cyclic dinucleotides using mass 
spectrometry, both mammalian and bacterial in circulation in vivo of both humans 
with severe ALD and mice after acute-on-chronic ALD. Furthermore, I propose 
administration of diguanylate cyclase inhibitors in vivo to inhibit c-di-GMP 
synthesis and secretion by intestinal bacteria after ethanol administration to 
determine if bacterial diguanylate cyclase is a viable therapeutic target to treat 
ethanol-induced liver injury. Finally, to visually assess the role of cyclic 
dinucleotides in relation to ethanol-induced zonal distribution of liver injury, 
creating an AAV-mediated biosensor for detection of cyclic dinucleotide binding 
would be very informative. To this end, I hypothesize that creating biosensors 
onto an AAV8-mediated in vivo riboswitch-lacZ reporter gene of cyclic 
dinucleotide signaling by injecting mice with an AAV8 vector encoding β-
galactosidase under control of a riboswitch-heptamere lacZ construct, so that 
cells responding to cyclic dinucleotide signaling are labeled by β-galactosidase 
expression.  
 222 
Lastly, as a therapeutic approach, if administration of diguanylate cyclase 
inhibitors is not effective or somehow has deleterious side-effects as part of the 
ethanol liquid diet, I propose an alternate approach to therapeutically target 
bacterial cyclic dinucleotides after they have crossed the intestinal wall via 
hepatic overexpression of PdeB, a c-di-GMP specific phosphodiesterase, using 
recombinant AAV8-mediated gene therapy. I hypothesize that ectopic expression 
of PdeB transgene via rAAV8 will drive hydrolysis of intracellular c-di-GMP, 
thereby reducing activation of STING and subsequent phosphorylation of IRF3.   
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MATERIALS AND METHODS 
Animal studies. All WT mice were obtained from Jackson Laboratory, Bar Harbor, 
ME as 6- to 8-week-old female C57Bl/6 WT. Littermate controls, bred at in our 
lab, were used for the uricase transgenic mouse experiments. IRF3-deficient 
(IRF3-KO) or type I IFN α/β receptor 1-(IFNAR1)-KO mice (provided by J. Sprent, 
Scripps Research Institute, La Jolla, CA, USA), Casp-1/11-KO (gift of A. Hise, 
Case Western Reserve University, Cleveland, Ohio, USA) and IRF7-KO mice 
(provided by T. Taniguchi, Tokyo, Japan), all on C57Bl/6 background, were used. 
The STING-deficient Tmem173gt (goldenticket) mice (provided by R. Vance, 
University of California, Berkeley, CA, USA,) and the TRAM-KO mice (provided 
by S. Akira, Osaka University, Japan) were on the B6.129sf2 background; we 
used B6.129sf2 WT mice (Jackson Laboratory) as controls for these two strains. 
Please refer to Table 2 for a list of mouse genotypes, genetic background and 
sourcing information.  
 
Ethanol administration. WT C57BL/6 6- to 8-weeks-old female mice were 
purchased from Jackson Laboratories and were cohoused in the University of 
Massachusetts Medical School Animal Medicine Facility for one week prior to the 
start of the experiment at which time they were doubly housed. Some animals 
were fed with the Lieber DeCarli ad libitum diet (chronic model) or received 
intragastric ethanol (5g/kg body weight, acute model). Mice were treated with an 
acute-on-chronic alcohol feeding model, as described by Bertola et al 92. Briefly, 
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all mice were fed the Lieber DeCarli pair-fed diet for five days to become 
acclimated to a liquid diet. Some mice were then switched to the Lieber DeCarli 
ethanol diet containing 5% ethanol and maltose dextran (to control for caloric 
intake). Pair-fed mice were calorie matched with the ethanol-fed mice. On the 
tenth day, mice were gavaged between midnight and 2am with either ethanol (5 
g kg-1 body weight) or iso-caloric maltose dextran. Mice were cheek bled then 
euthanized 9h post-gavage (9-11am), unless indicated otherwise. For 
assessment of peak phosphorylation of IRF3 or cleavage of inflammasome-
related proteins, the time-point of four-hours post binge ethanol was used. All 
animals in this study were cared for in accordance with the Institutional Animal 
Care and Use Committee regulations at the University of Massachusetts Medical 
School. 
 
In vivo treatment of mice. Some animals received a single dose of 25 mg/kg 
recombinant IL-1 receptor antagonist (IL-1Ra, Anakinra; Amgen). Anti-CD95 
antibody, clone: Jo2, 0.5 mg/kg (BD biosciences, San Jose, CA, USA), or saline 
was administered as a single i.p. injection. All animals received proper care in 
agreement with animal protocols approved by the Institutional Animal Use and 
Care Committee of the University of Massachusetts Medical School. 
 
Kupffer-cell depletion. WT mice were injected with 200 μL liposomal clodronate 
or liposomal PBS (purchased from N. van Rooijen, Free University Amsterdam, 
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Amsterdam, the Netherlands) via tail vein injection. 48 hours later, mice were 
sacrificed to evaluate KC depletion using F4/80 staining (CI:A3-1, AbD Serotec, 
Raleigh, NC, USA), or administered a single intragastric dose of ethanol.  
 
Primary hepatocyte isolation. Isolation of primary mouse hepatocytes and liver 
mononuclear cells was performed as follows: Mouse livers were perfused 
through the portal vein on anesthetized mice with Buffer 1 (0.5mM EGTA in 
HBSS) for 5 minutes, followed by Buffer 2 (25mg Collagenase + 0.5mM CaCl2 in 
HBSS per mouse) for 5 minutes, all pre-warmed to 37 degrees. Collagenase was 
reconstituted at a concentration of 100 mg/mL in HBSS + CaCl2 and aliquoted 
into 250 µL aliquots, with 25 mg of collagenase to be used per mouse liver to be 
perfused. Hepatocytes were separated from dissociated livers by spinning for 5 
min at 300g at 4 degrees. Cell pellet was washed three times with 2%FBS in 
PBS. 
 
In vitro experiments. Primary hepatocytes were cultured in Waymouth’s medium 
supplemented with 10% fetal bovine serum and 1% insulin, transferrin, selenium 
solution. Primary hepatocytes were seeded in 6-well collagen-coated plates 
(Biocoat, Becton Dickinson, Bedford, MA). Before starting stimulation 
experiments, hepatocytes were rested for 4 hours. Subsequently culture media 
was replaced, and stimulation was performed as indicated in the figure legends. 
The Jo2 antibody was purchased from BD biosciences (San Jose, CA, USA), 
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BX795, polyI:C and lipofectamine from Invitrogen (Life Technologies Corp., 
Grand Island, NY, USA), and thapsigargin (1μM) from Sigma (St. Louis, MO, 
USA). For mitochondrial DNA depletion in Huh7 cells, we incubated cells with 
ethidium bromide (0.2 µg/ml) and supplemented with 50 µg/ml uridine and 1 mM 
sodium pyruvate for 40 days to deplete mtDNA132. mtDNA depletion was 
confirmed by Cytochrome C Oxidase I (COX1) and NADH Dehydrogenase 
Subunit 6 (ND6) mRNA using Taqman probes (ThermoFisher Scientific).  
 
Biochemical assays. Serum ALT was determined using a kinetic method (D-Tek 
LLC., Bensalem, PA). Colorimetric assays were used to measure liver 
triglycerides (Wako Chemicals, VA, USA) and the LDH activity in cell culture 
supernatants (Abcam, Cambridge, MA, USA). ATP in serum or cell-free 
supernatant was measured using Cell-Titer Glo. A standard curve was made 
every time with freshly reconstituted ATP in water for accurate assessment of 
concentrations. Uric acid in serum or cell-free supernatant was measured using 
colorimetric assay at first. This process was later improved in sensitivity using 
fluorimetric measurements after 30min incubation at 37 degrees.  
 
Cytokine measurement. Levels of MCP-1 and TNF-α were measured using 
specific anti-mouse ELISA from Biolegend (San Diego, CA, USA). IFN-β was 
measured using specific anti-mouse ELISA from PBL (Piscataway, NJ, USA) and 
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cytochrome c and serum FasL was measured by ELISA kit from R&D (R&D 
systems, Inc., Minneapolis, MN). 
 
Protein quantification. Liver whole-cell lysates and nuclear preparations were 
extracted using RIPA buffer supplemented with protease and phosphatase 
inhibitor cocktails. Tissue and cells were homogenized using Qiagen’s 
TissueLyzer system, left on ice for 10 min, then spun at 10,000 RPM for 10 min, 
followed by removal of pelleted cell-debris. Lysates were quantified using 
Bradford assay or BCA assay. Lysates were then prepared using Laemlli loading 
buffer and boiled for 5 min. Mitochondrial and total ER fractions were prepared 
using specific extraction kits from Imgenex (San Diego, CA) as per 
manufacturer’s protocol. Antibodies for western blots and their associated 
dilutions are described in Table 3. Antibodies for loading controls were the 
following: total IRF3 (phospho-IRF3), GRP78 and KDEL (ER fraction), Beta-actin, 
beta-tubulin (whole-cell lysate), porin (mitochondrial fraction) and TATA-binding 
protein (TBP) (nuclear fraction). The TrueBlot system from eBioscience (San 
Diego, CA, USA) was used for immunoprecipitation assays and performed as per 
manufacturer’s instructions. 
 
RNA Analysis. Cells or tissue as stored in Qiazol at 4 degrees overnight. RNA 
was extracted from liver tissue or cells using RNeasy (Qiagen) according to the 
manufacturer’s instructions, including on-column DNase digestion (Zymo 
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Research). cDNA was written from 1μg of RNA and then diluted 1:5 in nuclease-
free water. SYBR Green (BioRad) real-time qPCR was performed according to 
the manufacturer’s instructions. The PCR primers used for RNA analysis are 
described in Table 1. For RT-PCR, 18S was used as a housekeeping gene for 2-
ddCt method of RNA expression analysis. For analysis of sXbp1 mRNA, PCR 
was performed and products were separated on 3% agarose gel. 
 
Histopathological analysis. Liver sections were stained with H&E, Sirius Red or 
Oil-red-O and analyzed by microscopy. Immunohistochemistry staining for F4/80 
(CI:A3-1, AbD Serotec, Raleigh, NC, USA) or TUNEL staining (Roche, 
Indianapolis, IN, USA), were performed in formalin-fixed, paraffin-embedded 
livers. OCT-embedded frozen liver sections were used for Oil-red-O staining, and 
quantification was performed using ImageJ to assess hepatic steatosis. 
Formalin-fixed paraffin-embedded liver sections were stained with anti-mouse 
myeloperoxidase (MPO) antibody, F4/80 CyclinD1 and Ki67, and subsequently 
labeled with streptavidin-biotin immunoenzymatic antigen for detection with 3,3’-
diaminobenzidine (DAB) (UltraVision Mouse Tissue Detection System Anti-
Mouse HRP/DAB; Lab Vision). ImageJ (NIH) was used for image analysis and 
quantification. 
 
Statistical Analysis. Statistical significance was determined using two-sided t-test; 
ANOVA and Dunnett’s multiple comparison post-test were used to compare the 
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means of multiple groups. Two-way ANOVA was used to determine the global 
effect of genotype on serum ALT. Mantel-Cox regression was used to assess 
statistical differences plotted in Kaplan Meier Survival analyses. Data are shown 
as mean ± SEM and were considered statistically significant at P < 0.05. We 
used Microsoft Excel, SPSS 19.0 (IBM SPSS, Chicago, IL, USA) and GraphPad 
Prism 7 (San Diego, CA, USA) for calculations. 
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Table 1. Table of Primers 
The qPCR primers used below were used for mouse gene targets. 
Gene Forward Primer Reverse Primer 
18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Tnfa CACCACCATCAAGGACTCAA AGGCAACCTGACCACTCTCC 
Mcp1 CAGGTCCCTGTCATGCTTCT CAGGTCCCTGTCATGCTTCT 
Pro-Il1b CTTTGAAGTTGACGGACCC TGAGTGATACTGCCTGCCTG 
Ifnb AGCTCCAAGAAAGGACGAACAT GCCCTGTAGGTGAGGGTTGATCT 
Xbp1 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
F4/80 TGCATCTAGCAATGGACAGC GCCTTCTGGATCCATTTGAA 
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Table 2. Table of Mouse Genotypes 
The mouse genotypes indicated below were used in these studies. Unless 
indicated, all mice used were 6- to 8-week-old female C57Bl/6 WT obtained from 
Jackson Laboratory, Bar Harbor, ME. 
Genotype Background Source 
IRF3-KO C57Bl/6 J. Sprent, Scripps Research 
Institute, La Jolla, CA 
IFNAR1-KO C57Bl/6 J. Sprent, Scripps Research 
Institute, La Jolla, CA 
Casp-1/11-KO C57Bl/6 A. Hise, Case 
Western Res. U., Cleveland, OH 
IRF7-KO C57Bl/6 T. Taniguchi, Tokyo, Japan 
Tmem173Gt B6.129sf2 R. Vance, University of California, 
Berkeley, CA, 
TRAM-KO B6.129sf2 S. Akira, Osaka University, Japan 
P2rx7-KO C57Bl/6 UMMS 
ssUOX-Tg C57Bl/6 K. Rock, UMMS 
intUOX-Tg C57Bl/6 K. Rock, UMMS 
NLRP3-KO C57Bl/6 A. Hise, Case 
Western Res. U., Cleveland, OH 
STING-KO C57Bl/6 K.A. Fitzgerald, UMMS 
cGAS-KO C57Bl/6 K.A. Fitzgerald, UMMS 
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Table 3. Table of Antibodies  
Target Catalog No. Source Dilution 
IRF3 sc-9082 Santa Cruz Biotechnology 1:400 
p-IRF3 CST#4947 Cell Signaling Technologies 1:1000 
TBK1 CST#3504 Cell Signaling Technologies 1:1000 
p-TBK1 CST#5483 Cell Signaling Technologies 1:1000 
STING CST#3337 Cell Signaling Technologies 1:1000 
BAX CST#2772 Cell Signaling Technologies 1:1000 
Caspase-3 CST#9665 Cell Signaling Technologies 1:1000 
Caspase-8 CST#4790 Cell Signaling Technologies 1:1000 
Cleaved Caspase-8 CST#9429 Cell Signaling Technologies 1:1000 
Caspase-1 p20 sc-22165 Santa Cruz Biotechnology 1:400 
Caspase-1 p10 sc-514 Santa Cruz Biotechnology 1:400 
IL-1β  sc-23460 Santa Cruz Biotechnology 1:400 
ASC sc-22514-R Santa Cruz Biotechnology 1:400 
NLRP3 CST#15101 Cell Signaling Technologies 1:1000 
Cleaved PARP CST#9544 Cell Signaling Technologies 1:1000 
β-actin ab49900 Abcam 1:20,000 
GRP78 sc-1050 Santa Cruz Biotechnology 1:400 
Bip CST#3183 Cell Signaling Technologies 1:1000 
8-OHdG Sc-139586 Santa Cruz Biotechnology 1:400 
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